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Copper amine oxidases (CAOs) are ubiquitously expressed in nature but vary
with regard to their substrate specificity and their role in various organisms.8-11 In
bacteria, CAOs serve to break down amines to supply the sole source of carbon or
nitrogen.9,13 In plants, the H2O2 formed in CAO catalysis is proposed to play a role in
cell wall formation and wound healing.16 In higher organisms, the role of amine
oxidases is more complex. Three CAOs have been identified in a variety of tissues in
the human body and have potential roles in regulating the level of biogenic amines,
reducing inflammation, and cell signaling.17-21 Lysyl oxidase (LOX), another copper-
containing amine oxidase, is known to play a role in stabilizing the extracellular
matrix by forming cross-links in collagen and elastin.22,23 It has been shown to play a
role in metastatic breast cancer along with other cancers in humans.24
The biogenesis of the topaquinone (TPQ) cofactor of copper amine oxidase
(CAO) is a self-catalyzed process that requires copper and molecular oxygen.  A
putative dopaquinone (DPQ) intermediate has been proposed to react with a copper-
associated water molecule, through a 1,4-addition mechanism, to form the reduced
form of TPQ (TPQred). An oxidation reaction by O2 yields the mature TPQ (TPQox).
Site-directed mutagenesis was used to incorporate a lysine residue into the active site
of a phenethylamine oxidase from Arthrobacter globiformis (AGAO) producing
D298K-AGAO.  The X-ray crystal structure of the mature form of D298K-AGAO
revealed the formation of a covalent linkage between the !-amino side chain of
Lys298 and the C2 position of the proposed DPQ intermediate.  The quinone formed
was proposed to be an iminoquinone tautomer (LTI) of lysine tyrosylquinone (LTQ),
the organic cofactor of lysyl oxidase (LOX). UV/vis and resonance Raman
spectroscopic studies of the time course of the formation of LTI at pH 6.8 detected an
LTQ-like intermediate in the early phase of the reaction, which slowly converts to
LTI. The LTI form of the tautomer is stabilized by hydrogen bonding interactions
with the conserved tyrosine residue (Tyr284) in the active site. The results of this
study strongly support the proposal that DPQ is an intermediate, not only in TPQ
biogenesis, but also in the biogenesis of LTQ in LOX.  This study also indicates that
DPQ, in the biogenesis of TPQ, is mobile and can leave the copper site to react with
Lys298.
A study of the pH-dependency on the rate of formation of the LTQ-like
cofactor in D298K-AGAO showed that the protonation states of two residues
influence the rate. The residue with a pKa of 7.93 ± 0.10 is deprotonated when the rate
of the reaction was the fastest and we propose that it is the precursor tyrosine (Y382),
while the residue with a pKa of ~ 9.62 ± 0.13 is protonated when the rate of the
reaction was the fastest and is proposed to be Tyr284. Tyr284 is most likely in
hydrogen bonding interaction with DPQ to facilitate the 1,4-addition of K298 side
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chain. TPQ was not detected at pH range studied (6.8 to 9.5) for D298K-AGAO
biogenesis. Although the mutation at D298 is not expected to alter the environment
around the active site copper, 1,4-addition of K298 side chain to DPQ has out
competed the 1,4-addition of a copper-associated water molecule. A 370 nm species
was observed in the initial seconds of the biogenesis reaction. This species is most
likely a charge-transfer species formed between the active site copper and a Tyr in the
active site of CAO but found not to be on the reaction pathway to form the quinone
cofactor.
The addition of n-butylamine hydrochloride in the biogenesis of WT- and
D298A-AGAO resulted in the formation of an LTQ-like quinone but prevented the
formation of TPQ. Each biogenized protein, containing the LTQ-like cofactor,
showed a 40- to 1000-fold reduced activity towards substrate amine when compared
to WT AGAO with TPQ cofactor.  The LTQ-like quinone in those enzymes is
predicted to have an increased mobility when compared to the LTQ-like cofactor in
D298K-AGAO, but it was not reactive towards inhibitor.  These results suggest that
the putative LTQ-like cofactor formed in the reaction between WT- or D298A-
AGAO and n-butylamine, has some mobility, and can be in the active conformation.
Further, the formation of an LTQ-like cofactor in WT-AGAO occurs at a rate that is
slower than the rate of LTQ cofactor formation in D298A indicating that the active
site of D298A is better arranged to facilitate the amination reaction.
An attempt was made in order to generate a TPQ cofactor in LOX was made
to confirm the proposal that DPQ is an intermediate in LTQ formation. In addition to
the possibility of forming TPQ, it is possible that the reaction would be incomplete
and DPQ would be observed directly. The mutation of Lys653 to Ala in a
recombinant form of HLOXL2 resulted in the formation of a mis-folded protein that
was expressed mainly as an inclusion body in Drosophila S2 cells as opposed to
soluble secreted WT-protein. Although the conclusive identification of DPQ as an
intermediate on the pathway to form LTQ was not confirmed, this result shows that
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Post-Translationally Derived Cofactors
Several types of post-translational modifications, such as methylation,
glycosylation, and cleavage of signal peptides, have been identified that regulate
protein activity.25 Cofactors, such as FAD, heme, pyridoxal phosphate (PLP),
pyrroloquinoline quinone (PQQ), and NAD+, are utilized by enzymes to assist in
biochemical transformations. These transformations would otherwise be impossible
due to the limited capability of amino acid side chains to perform a variety of
chemical reactions. Most amino acid side chains are inert, while others, such as
acidic, basic, and aromatic residues, have limited function in acid-base chemistry and
electron transfer reactions. Previously, a cofactor was defined as a metal or small
organic compound that is not composed of amino acids but is required for enzymatic
activity. More recently, however, a new class of post-translational modifications have
been identified, protein-derived cofactors, that participate in enzyme catalysis or
redox chemistry.26 Protein-derived cofactors are covalently attached to the protein and
are usually derived from aromatic residue oxidation, amino acid cross-linking, or
2
amino acid cyclization. These cofactors are mostly located in the active site of
proteins and facilitate chemistry that the unmodified amino acids could not.
Quinone Cofactors
PQQ is a cofactor that is frequently found in proteins that metabolize small
molecules. It has been extracted from methanol dehydrogenase, indicating that it is
not covalently bound to the proteins.27,28 The first protein-derived cofactor to be
identified was 2,4,5-trihydroxyphenylalanine quinone (TPQ) in 1990 in bovine serum
amine oxidase (BSAO), which was initially believed to be a covalently attached PQQ
cofactor.26 Since then, three additional quinone cofactors have been reported,
including both tyrosine- and tryptophan-derived quinone cofactors (Figure 1.1). The
tyrosine-derived quinone cofactors are TPQ of copper-containing amine oxidase
(CAO) and lysine tyrosylquinone (LTQ) of lysyl oxidase (LOX). Tryptophan
tryptophylquinone (TTQ) of methylamine dehydrogenase (MADH) and cysteine
tryptophylquinone (CTQ) of quinohemoprotein amine dehydrogenase (QHNDH) are
both tryptophan-derived cofactors. The biogenesis of the tyrosine-derived cofactors
occurs through an autocatalytic process requiring only Cu2+ and O2,
2,29,30 while the
biogenesis of TTQ requires the action of four gene products, mauD, mauE, mauF and
mauG, in addition to the two that encode for the alpha and beta subunits, mauA and
mauB, of the MADH protein.31,32 The biogenesis of CTQ is less understood but,
likely requires additional genes that have not yet been identified.33,34 Each of these
cofactors catalyzes the deamination of substrate amines to their corresponding
3
aldehydes with concomitant production of an ammonium ion; however, the tyrosine-
derived cofactors are oxidases that transfer electrons to O2 producing H2O2, while the
tryptophan-derived cofactors are dehydrogenases that transfer electrons to external
electron acceptors such as amicyanin, azurin, and cytochrome C550.
Figure 1.1 Post-translationally derived quinone cofactors. A) 2,4,5-
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CAO and the TPQ Cofactor
CAO (EC 1.4.3.6) catalyzes the oxidative deamination of various primary
amines to produce their corresponding aldehydes concomitant with hydrogen
peroxide and ammonia (Equation 1.1).35
RCH2NH3
+   +   O2  +  H2O  $  RCHO    +    NH4
+   +   H2O2 (1.1)
CAOs are ubiquitously expressed in nature but vary with regard to their substrate
specificity and their role in various organisms.8-11 In bacteria, CAOs serve to break
down amines to supply the sole source of carbon or nitrogen.9,13 In plants, the H2O2
formed in CAO catalysis is proposed to play a role in cell wall formation and wound
healing.16 In higher organisms, the role of amine oxidases is more complex. Three
CAOs have been identified in a variety of tissues in the human body and have
potential roles in regulating the level of biogenic amines, reducing inflammation, and
cell signaling.17-21
All of the solved crystal structures of CAO show a homodimeric protein
containing one TPQ and one copper per subunit (Figure 1.2).9,26,36-41 Each monomer
contains three domains with the exception of E. coli amine oxidase (ECAO) that has
an additional N-terminal domain (D1).9,42 The C-terminal domain (D4) contains a #-
sandwich and the protein active site. Additionally, this domain has two long #-hairpin
arms that reach across from the D4 of one monomer to the D4 of the other. Although
the overall structures of the CAOs are similar, the catalytic domain (D4) shares ~20%
5
sequence identity among all the known species of CAOs.43 These differences likely
account for the variation in substrate specificities among the CAOs from different
species.44 For example, the substrate entry channel of hVAP-1 is rich in aromatic and
hydrophobic residues and appears to be gated by a Leu residue.45 However, in
AGAO, the substrate entry channel is lined with negatively charged residues that are
more hydrophobic towards the active site and Tyr302 is proposed to be the gate.9,46
TPQ, however, is derived from a conserved tyrosine residue in the consensus
sequence N-Y-D/E-Y/N.29
In the active (holo) form of AGAO, three histidines ligated to the copper
along with two water molecules; one of the water molecules is on the Jahn-Teller axis
(Wa) and the other is in the equatorial position (We) to provide a distorted square
Figure 1.2 Secondary structure of the AGAO homodimer. The three domains of
monomer A are shown in light blue (D2), cyan (D3), and blue (D4). Monomer B
is shown in grey. Copper is shown as a yellow sphere and TPQ is shown as green
sticks. The red circle indicates the location of the active site with TPQ and
copper.
6
pyramidal coordination geometry (Figure 1.3).12 The C5 carbonyl group of TPQox is
facing the proposed substrate entry channel9 and the conserved aspartate residue
(Asp298) is proposed as an active site base.11 Xe binding studies of AGAO indicate
that the single hydrophobic O2 binding site is on the opposite side of the active site
from the substrate entry channel. O2 bound in this site would be 7 Å from Cu
2+ and 9
Å from TPQ.47 Similar Xe binding studies on HPAO indicated that there are two O2
binding sites near the active site; one is consistent with the O2-binding site predicted
for AGAO and another is in an adjacent hydrophobic pocket.48 In HPAO, mutation of
residues intended to inhibit O2-binding in either site or mutation of residues in
potential O2-entrance channels did not alter activity, indicating that multiple channels
are available to O2 and that the importance of various O2-binding sites vary from
species to species. This study also indicated that the hydrophobic core of the #-
















Xe binding studies on BSAO indicated that there is a potential O2-binding site
8.6 Å from Cu2+ on the opposite side of Cu2+ from TPQ.40 It is located in a
hydrophobic pocket with a phenylalanine side chain between the pocket and Cu2+. An
additional Xe signal was observed between Cu2+ and TPQ and is in a position where
O2 has been predicted to bind in ECAO. Another Xe signal was observed on the
opposite side of TPQ from the Cu2+ and is proposed to be a hydrophobic region in the
wedge shaped cavity where small apolar molecules, or apolar portions of substrates,
interact with the cavity.
The C2 carbonyl group of TPQ interacts with the copper through hydrogen
bonding with a conserved water molecule, but neither O2 nor O5 are directly ligated
to the copper.  This orientation of the TPQ ring is critical for the optimal activity of
CAO (Figure 1.4 a).7 At neutral pH, TPQ exists in a resonance stabilized mono-
anionic form with charge delocalization between the C2 and C4 carbonyls.49,50 This
delocalization of charge directs nucleophilic attack to the C5 carbonyl group.50,51 In
AGAO, resonance Raman studies indicate that the C5 oxygen of TPQ has more
double bond character than the C2 or C4 oxygens, which explains why nucleophilic
attack by substrate occurs only at this position.52 Additionally, in HPAO, the C5
oxygen of TPQ exchanges with solvent water molecules.52 This observation supports
its proposed reactivity.
The mobility of TPQ and TPQ-derived reaction intermediates in CAOs are
tightly controlled by hydrogen bonding interactions, particularly between the O4 of
TPQ and the conserved Tyr (Tyr284 in AGAO) for optimal activity (Figure 1.4 a).7
8
The TPQ ring is located in a wedge shaped cavity in the active site, but the mobility is
limited to pivoting inside of the wedge (Figure 1.4).7,15 When these hydrogen bonding
interactions are disrupted by high salt (Figure 1.4 d), lowering pH (Figure 1.4 b), or
Figure 1.4 Active site structures of holo CAO.7 a) Active conformation of AGAO
(PDB code 1IU7 at 1.8 Å resolution).12 b) Flipped conformation of AGAO (PDB
code 1AV4 at 2.2 Å resolution).9 c) Flipped and swung conformation of ECAO
Y369F (PDB code 1JRQ at 2.15 Å resolution).15 d) Cu-on conformation from
AGAO (PDB code 1AVL at 2.8 Å resolution).9 TPQ, the active site base, and the
conserved Tyr (mutated to F is panel c) are green. The copper binding site is grey.
Copper is shown as a golden sphere. The active site waters are blue. * indicates



















site-directed mutagenesis (Figure 1.4 c), the TPQ ring gains mobility and swings out
from the wedge and can ultimately be trapped by ligation to the active site Cu2+, all of
which lead to greatly reduced catalytic activity.  Disruption of the hydrogen bonding
network by lowering the pH (Figure 1.4 b) shows an electron density map with
density seen for the O4 atom but not for the aromatic ring, O2, or O5 indicating that
the ring is free to rotate in the active site.
CAO Catalysis
The catalysis of primary amines to their corresponding aldehyde, proceeds









































Scheme 1.1 Proposed reaction mechanism of the catalytic cycle of CAO. %The
reductive half-reaction, % the oxidative half-reaction.
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half-reaction (Scheme 1.1).35 The reductive half-reaction initiates when the substrate
enters the negatively charged substrate entry channel that becomes hydrophobic
closer to the active site,9 is deprotonated, potentially by the active site base (D298 in
AGAO), and undergoes nucleophilic attack on the C5 carbonyl of TPQ to form the
substrate-Schiff base (SSB). The SSB is converted to the product-Schiff base (PSB)
by the abstraction of the substrate C1 proton by a conserved aspartate residue, and
two electrons are transferred from the amine of the substrate to the oxidized TPQ. 49
The proton abstraction step in the reductive half-reaction has been shown to be
stereospecific, determined by the arrangement of the active site.53 Mutation of the
active site base, D383 in ECAO or D298 in AGAO, indicates that the active site base
is responsible for proton abstraction, and it is involved in positioning the substrate in
the active site.15,46,54 PSB hydrolysis releases the product aldehyde and forms an
aminoresorcinol like reduced cofactor (TPQred) that exists in equilibrium with a Cu(I)-
semiquinone (TPQsq). The rate limiting step in the reductive-half reaction is
dependent on the source of the CAO and the mutation of active site residues. C-H
bond cleavage may be more rate-limiting in some enzymes. For example, it appears
to be more rate-limiting in BSAO than in HPAO.55 While in HPAO, C-H bond
cleavage is more rate-limiting with butylamine than with methylamine as a substrate.
Conformational changes in the active site have been suggested to be rate-limiting in
D319E of HPAO.54
The SSB and PSB of ECAO have been shown to have some conformational
flexibility.56 In HPAO, mutation of the tyrosine corresponding to Tyr284 in AGAO,
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or of the residues flanking TPQ to alanine, led the the accumulation on a neutral form
of the PSB (catalytically active PSB is the monoprotonated form) that slowly
hydrolyzes; PSB was proposed to be in the flipped conformation.30,55,57 Mutagenesis
studies on ECAO showed that residues D383 and Y369, corresponding to D298 and
Y284 of AGAO, are involved in limiting the mobility of the SSB and PSB.56 When
TPQ of ECAO was reacted with 2-hydrazinopyridine (2-HP), the 2-HP adduct was
mainly in the hydrazone form as opposed to the azo form of the tautomer due to
interactions between D383 and the pyridine ring of the TPQ adduct; the rings of TPQ
and pyridine were not coplanar. When D383 was mutated to Ala or when Y369 was
mutated to Phe, the equilibrium between hydrazone and azo forms of the tautomer
shifted to the azo form. Additionally, by heating or increasing the pH of the enzyme
solution, a new species was observed that was identified as the on-copper form of the
TPQ-2HP cofactor. In the Y369F mutant, the species is formed at room temperature,
indicating that the hydrogen bonding interaction between the O4 of TPQ and Y369
has a role in keeping TPQ in the active, off-copper, conformation.56
In the oxidative half-reaction, O2 accepts electrons from TPQred to produce
H2O2 and an iminoquinone (TPQimq).
58 The TPQimq can undergo hydrolysis to
regenerate the resting cofactor, TPQox, and NH4
+ or, most likely, it undergos a
transimination reaction with substrate to generate the SSB and NH4
+.9,35,51 An 18O
kinetic isotope effect study in BSAO and HPAO showed that the electron transfer
from TPQred to O2 was the rate-limiting step in the oxidative half-reaction.
58,59
Additionally, the effect of solvent viscosity on the rate of oxidation suggested that O2
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was prebound in the active site, and the binding of O2 was not responsible for the
observed kinetic isotope effect.58 As discussed above, O2 bound in the proposed O2
binding site would be ~ 7 Å form the Cu2+ and ~ 9 Å from the TPQ.47 Electron
transfer from either Cu2+ or TPQ would require the O2 molecule to move 4 – 6 Å. It is
possible that O2 reacts with either the Cu(I)-TPQsq or with Cu(II)-TPQred.
12,60
Additionally, Co2+ and Ni2+ substituted forms of the enzyme show 1000-fold
decreased rate in the oxidative half-reaction.12 Various studies on CAOs from
different sources suggest that the mechanism of reoxidation of the cofactor may vary
from species to species.12,61-63
TPQ Cofactor Biogenesis
The mechanism of TPQ biogenesis has been studied for AGAO5,9,64-68 and
HPAO.14,55,69-74 The biogenesis of the TPQ cofactor is a self-catalyzed reaction,
requiring only copper and oxygen.29,30 The biogenesis can be initiated by addition of
Cu2+ to the apo-protein under aerobic conditions or exposure of the Cu2+-bound
precursor protein prepared under anaerobic conditions to O2.
75 The copper-free
tyrosine precursor (apo) form of recombinant CAO can be prepared by removing
copper from the buffers used during purification.  In AGAO, the ratio of O2
consumption to hydrogen peroxide formation is 2:1; 1 mol of H2O2 was produced per
mole of TPQ formed (Equation 1.2), and the rate of TPQ formation is approximately
that of H2O2 formation.
65 The rate of the reaction was zero-order in copper with
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concentrations of one equivalent or more.64 Mechanisms have been proposed that
account for this stoichiometry (Scheme 1.2).
E-Tyr  +  2O2  +  H2O  $  E-TPQ  +  H2O2                         (1.2)
In 2004, Kim et. al. performed an X-ray snapshot analysis in an attempt to
freeze trap the reaction intermediates of TPQ biogenesis in AGAO (Figure 1.5).5 The
structure of the apo form of AGAO revealed that the phenolic hydroxyl group of the
precursor tyrosine (Tyr382) pointed towards the vacant metal site composed of the



































































three conserved histidine residues (His431, His433 and His592).5,9 When apo protein
crystals were soaked with copper anaerobically, copper was bound in a tetrahedral
geometry to the three His ligands, and Tyr382 provided the fourth ligand (Figure 1.5
a).  A similar observation of the precursor tyrosine ligation to the metal was seen in
the crystal structure of zinc-substituted HPAO that remains unprocessed.76 Upon
exposure of the unbiogenized copper bound crystals to molecular oxygen, two
Figure 1.5. Proposed mechanism of TPQ biogenesis.5  Panels a, b, d, e are
intermediates observed in the X-ray snapshot analysis. Copper is shown as a
golden sphere and water molecules are shown in light blue spheres.  a) Tyr:
Tyr382 precursor, b) DPQ: dopaquinone, c) proposed DPQ in a flipped form, d)
TPQred: 2,4,5-trihydroxylbenzene form of the reduced TPQ, e) TPQox: the oxidized




copper-bound intermediates, proposed to be dopaquinone (DPQ, Figure 1.5 b) and
trihydroxybenzene (TPQred, Figure 1.5 d), respectively, were detected where the O4
hydroxyl group of the aromatic ring remained directly coordinated to Cu2+.  During
the conversion of the putative DPQ to TPQred, the aromatic ring rotated 180° to
undergo hydration by a copper-associated, solvent exchangeable water molecule
(Figure 1.5 c), as shown by resonance Raman studies on AGAO.66 In the final step of
the oxidation of TPQred to TPQox, the TPQ ring finally moved off Cu
2+ to leave the
cofactor in the active conformation (Figure 1.5 e).  As a result of the conformational
changes during biogenesis, the TPQ ring in the mature AGAO is in a different
orientation from the precursor tyrosine (Figure 1.5 a).  The C2 carbonyl of the TPQ
ring is directed toward the five-coordinate distorted square-pyramidal copper where
two water molecules have taken the place of the O4 atom of TPQ.
When Co2+ or Ni2+ is substituted for Cu2+, the metal has a six coordinate,
octahedral geometry with the addition of a second water molecule.68 Co2+, Ni2+, and
Zn2+ can all bind tightly to the metal binding site of CAO but only Co2+ and Ni2+ are
capable of producing an enzyme with a fully biogenized TPQ cofactor. The rates of
biogenesis of the Co2+ and Ni2+ substituted enzymes were reduced to 2.2% and 0.9%,
respectively, of the rate in WT AGAO.12 However, in AGAO and HPAO, metal
substitution does not affect the rate of substrate catalysis.12,77 Kinetic studies on the
biogenesis of TPQ in Ni2+-substituted HPAO indicated that the electron transfer from
the metal-coordinated tyrosinate to O2 is the rate-limiting step in the reaction.
73
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In contrast to mature TPQ, the possible mobility of the reaction intermediates
in the TPQ biogenesis has not been considered. From the X-ray snapshot analysis, the
precursor Tyr382 is initially bound to the Cu2+ residing outside the active site wedge
(Figure 1.5 a).5 Both the proposed DPQ intermediate and TPQred are both still
interacting with Cu2+ (Figure 1.5 b, 1.5 d).  Upon oxidation of TPQred to TPQox, TPQ
finally leaves the active site Cu2+ and swings into the wedge to be captured by Tyr284
to be in the active conformation (Figure 1.5 e).  It is not known what factors cause
TPQox to leave the Cu
2+ site.
Detailed kinetic and spectroscopic studies on the biogenesis of TPQ in HPAO
revealed that the rate-determining step is the decay of a species absorbing at 350 nm
that is proposed to be a Cu2+-tyrosinate complex and exists in equilibrium with a
Cu1+-tyrosyl radical (Scheme 1.2).72 The decay of the 350 nm species and the
formation of TPQ occur concomitantly with an isobestic point indicating a precursor-
product relationship.70 The absence of a kinetic isotope effect on the rate of TPQ
formation using the 3,5-ring dideuterated tyrosine precursor excluded the possibility
that subsequent C-H bond cleavage step from a proposed Cu2+-aryl-peroxide
intermediate was rate-limiting (Scheme 1.2).14 No spectroscopic intermediates were
detected during the conversion of the 350 nm species to mature TPQox absorbing at
472 nm.  In AGAO, binding of Cu2+ to the precursor protein under anaerobic
conditions does not appear to lead to the formation of any distinct new features in the
UV/vis spectrum, in contrast to HPAO.64 When O2 was introduced to the system,
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rapid formation of mature TPQox (478 nm) was observed, where the reaction was
complete within a couple of minutes.
The roles of various active site residues have been explored using site-directed
mutagenesis. N-Y-D/E-Y (Y is the precursor of TPQ) consensus sequence residues of
histamine oxidase from A. globiformis were mutated to N401D/Q, D403E/N and
Y404F.78 Reduced rates of biogenesis were seen in N401D/Q and D403N, but the
rates of biogenesis in D403E and Y404F were comparable to wild-type protein. These
results, along with those of E406Q and N404D from HPAO57 have indicated that
these residues are important in determining the rate of TPQ biogenesis. The catalytic
base, D298 in AGAO, has not been proposed to be directly involved in cofactor
biogenesis, but the rate of TPQ formation in the D298A mutant was ~ 40% of that
seen in WT. The mutation of the strictly conserved active site Y305 from HPAO to
alanine or phenylalanine slowed the rate of biogenesis by ~45-fold and 3-fold,
respectively.74 The variation in rates indicates that the bulkiness of the residue is
important in restricting the movement of the precursor tyrosine or biogenesis reaction
intermediates. Additionally, this mutant formed a new species ~400 nm, particularly
at higher pHs, that is, most likely, a Cu-on TPQox.
49
LTQ Cofactor Biogenesis in LOX
Lysyl oxidase (LOX) is also a copper-containing amine oxidase but differs
from CAO by being monomeric (32 kDa) and having a lysine tyrosylquinone (LTQ,
see Scheme 1.3) cofactor.3 It is known to play a role in stabilizing the extracellular
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matrix by forming cross-links in collagen and elastin.22,23 A model study suggested
that 1,4-addition of the !-amino side chain of lysine to the DPQ intermediate can
form the LTQ cofactor, where the active site of LOX must be pre-organized to
achieve the selectivity of the reaction (Scheme 1.3).1 Recently, Bollinger et al.
isolated the copper-free precursor form of recombinant LOX (apo-LOX) and showed
the formation of the LTQ cofactor by extensive dialysis of the apo-LOX against
copper under aerobic conditions.2 They proposed that the biogenesis of the LTQ
cofactor is a self-catalyzed process requiring only Cu2+ and molecular oxygen as in
the case of the TPQ cofactor in CAOs. In order to identify the residues participating
in the crosslink to form LTQ, a mutagenesis study was done on LOX from a rat aorta
expressed in Chinese hamster ovary (CHO) cells.3 Mutagenesis of Lys314 and
Tyr349, the precursors for the LTQ cofactor, followed by activity assays, showed that
both single and double mutants of these residues were inactive. However, the mutants
from this study were not fully characterized. Taken together, these results support
proposals that both TPQ and LTQ biogenesis proceed through a DPQ intermediate.




The overall goal of this research is to determine if DPQ is a common
intermediate on the pathway to form TPQ in CAO and LTQ in LOX in order to
support the proposed mechanisms of TPQ and LTQ formation. In an attempt to
definitively identify DPQ as the intermediate in the biogenesis of TPQ and to provide
support for the intermediacy of DPQ in the biogenesis of LTQ, a lysine residue was
incorporated into the active site of AGAO by site-directed mutagenesis to trap the
putative DPQ intermediate. Research presented herein characterizes the cofactor
formed in D298K by UV/vis and resonance Raman spectroscopy.
While determining that DPQ is an intermediate in the biogenesis of TPQ and
supporting the proposed intermediacy of DPQ in the biogenesis of LTQ, the research
indicated that the 1,4-addition of a lysine side chain to DPQ in the biogenesis of an
LTQ-like cofactor in AGAO occurred selectively at pH 6.8 without competition from








































hydration. Thus, a secondary goal of this research was proposed to determine if the
hydration reaction (to form TPQ) competes with amination (to form LTQ) at lower or
higher pHs. The pH-dependency on cofactor formation was studied along with the
pH-dependency on the rate of biogenesis of the LTQ-like cofactor in the D298K
mutant.  Observations made during this study suggested a further goal of this
research: to characterize the species initially forming at ~370 nm in D298K
biogenesis by UV/vis spectroscopy.
Additionally, the LTQ-like cofactor generated during the initial DPQ trapping
study was generated by the cross-linking of two amino acid residues causing it to be
trapped in the flipped, inactive conformation. Another secondary goal of this research
was to generate and characterize an LTQ-like cofactor in CAO that has increased
mobility and could potentially exist in the active conformation; thus, a D298A mutant
was biogenized in the presence of a free amine.
Lastly, in order to assess the intermediacy of DPQ in the biogenesis of LTQ in
LOX and to determine if the active site of LOX is selectively set up to generate LTQ
or capable of catalyzing the formation of TPQ (hydration reaction of DPQ), the lysine
participating in the cross-link to form LTQ was removed from the active site of
HLOXL2 by site-directed mutagenesis.
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Chapter 2: Trapping a DPQ Intermediate in the Biogenesis of TPQ in AGAO
This chapter is reproduced in part with permission from Moore, R. H.; Spies, M. A.;
Culpepper, M. B.; Murakawa, T.; Hirota, S.; Okajima, T.; Tanizawa, K.; Mure, M.
Journal of the American Chemical Society 2007, 129, 11524-11534. Copyright 2007
American Chemical Society.
Introduction
Designing Active-site Mutants to Trap Dopaquinone in TPQ Biogenesis.
As discussed in chapter 1, a dopaquinone-like intermediate (DPQ) has been
observed in the biogenesis of TPQ using time-resolved X-ray crystallography, but the
redox state of the intermediate was not defined at 2.1 Å resolution (Figure 1.5 b). A
resonance Raman spectroscopic study confirmed that the C2 oxygen of TPQ was
derived from a solvent water molecule and strongly supported the proposed reaction
mechanism involving 1,4-addition of water to the C2 position of a DPQ
intermediate.66 By analogy, DPQ has been suggested as an intermediate in LTQ
biogenesis.  In a model study, it was shown that 1,4-addition of N-methyl-n-
butylamine to the C2 position of DPQ forms the LTQ-like quinone and the active site
of LOX must be pre-organized to prevent a 1,2-addition reaction.1   In order to gain
insight into the intermediacy of DPQ both in the TPQ and LTQ cofactor biogenesis, a
lysine residue was incorporated in the active site of AGAO in two positions in an
attempt to trap the DPQ intermediate either before flipping (Figure 1.3 b) or after
flipping (Figure 1.3 c) and to generate a LTQ-like cofactor in CAO.  Based on the
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model chemistry,1 a correctly placed amine should be able to effectively trap the
putative DPQ intermediate, thereby forming an LTQ-like-quinone.  Based on the X-
ray crystal structure of the putative DPQ intermediate,5 a mutation of Asp298 was
performed to trap the un-flipped conformation (Figure 2.1 a). To determine which
residue to target for the flipped conformation, the X-ray structure of TPQred (Figure
1.3 d) was used as a model for flipped DPQ.  Based on this, Met602 was found to be
the closest residue to the C2 carbon (Figure 2.1 b).
X-ray Crystal Structure of D298K.
The Tanizawa group (Osaka University) determined the crystal structure of




Figure 2.1 Active site structures of DPQ intermediates. Intermediates are shown in
un-flipped (a) (PDB code 1IVV at 2.1 Å resolution) and flipped (b) conformations.
The flipped conformation (b) of the DPQ intermediate is generated from the
reduced form of TPQ (TPQred) (PDB code 1IVW at 1.8 Å resolution). The DPQ is
green, D298 or D298K is magenta and M602 or M602K is blue.  H431, H433,
H592 (copper binding site) are light blue.  Copper is shown as a golden sphere.
Remaining active site residues are gray. Figures are generated by Pymol (DeLano
Scientific LLC, http://www.pymol.org).
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Lys298 and the C2 atom of the side chain aromatic ring of TPQ382 was apparent
even before introducing the cofactor model to the residues at the 298 and 382
positions.  Then, two models including the cross-link were examined at residues 298
and 382 for a best fit compared with the electron density.  One was LTQ, and the
other was the iminoquinone tautomer of LTQ (LTI) (Scheme 2.1).  The latter model
indicates that an imine bond is formed between the C2 carbon of the DPQ and the
side chain !-amino group of Lys298.  The dictionaries for these two models were
created by linking the C2 atom of the DPQ and the !-amino group of Lys298 through
distinct types (single or double) of a covalent bond whose lengths are
indistinguishable crystallographically at the present resolution.  The extra electron
density at the O5 position was very clear, suggesting a carbonyl group.  The two
models fitted equally well to the electron density in the Fo – Fc simulated annealing
(sa) omit map viewed perpendicularly to the dopaquinone ring (Figure 2.2 a, c).
However, close inspection of the lysyl side chain portion of the models revealed that
the LTI model fit better to the omit map than the LTQ model.  Particularly in a view














parallel to the dopaquinone ring, both of the N! and CE atoms of Lys298 are
positioned nearly in the middle of the electron density in the LTI model (Figure 2.2
d), whereas those in the LTQ model are located in the periphery of the electron
density (Figure 2.2 b).  The plane of the quinone ring is also better accommodated
inside the electron density in the LTI model than in the LTQ model. The planarity is
extended to the CE atom of Lys298 (Figure 2.2 d) and is permitted only for the sp2 N!
atom of LTI.  These data suggested that the cross-link formed between dopaquinone
Figure 2.2 Electron density map of the active site of D298K at 1.7 Å resolution.
Simulated annealing (sa) omit maps (contoured at 4.5 ') are shown with the
structure models of LTQ (a, b) and LTI (c, d).  a, c) Views perpendicularly to the
dopaquinone ring.  b, d) Views parallel to the dopaquinone ring.  Red arrows
show N! atoms of Lys298.4
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and Lys298 has an imine double bond character and that the quinone is stabilized as
LTI rather than LTQ.  The O4 of TPQ is in hydrogen bonding contact with the
conserved Tyr284 in WT. A similar hydrogen bonding interaction appears to be
present in D298K, which may help to stabilize LTI over LTQ (Figure 2.3). The
orientation of LTI in D298K is in a flipped, inactive conformation where the active
carbonyl group at C5 is facing away from the proposed substrate entry channel.9
Along with 1,4-additions to DPQ, 1,6-additions could also potentially occur.
In nature, o-quinones react with amino acid side chains, such as lysine, cysteine, and
histidine, in 1,2-, 1,4-, and 1,6-additions.  The addition reactions initiate
polymerization, and are a source of pigmentation in a variety of plant and animal
species.79,80 Studies of the reaction between o-quinone and cysteine occurring in
Figure 2.3 Active site structure of D298K and the putative dopaquinone
intermediate seen in TPQ biogenesis in WT.  a) D298K (PDB code 2YX9 at 2.7
Å resolution). Copper is shown as a golden sphere and water molecules are shown
in light blue spheres. Val282 and Asn381 forming a wedge-shape pocket are











insects have shown that 1,6-additions to o-quinones are preferred to 1,4-additions.81
Additionally, a model study of the reaction between o-dopaquinone and N-
acetylcysteine in the presence of oxygen resulted in the formation of the 1,6-addition
product, but the 1,4-addition product was not observed.82 In the biosynthesis pathway
of pheomelanin, a type of melanin with a red hue, cysteine is added to dopaquinone
through a 1,6-addition forming the catechol, cysteinyldopa (Figure 2.4).83,84
Cysteinyldopa has been detected in the plasma and urine of individuals with
melanoma.85 Cysteinyldopa levels are monitored in patients who have had melanoma
due to its usefulness as a specific and sensitive marker in the prediction of metastases.
In order to determine if DPQ in CAO could be trapped by a 1,6-addition, a cysteine









HEPES, MES, CHES, ammonium sulfate, sodium hydroxide, potassium
hydroxide, hydrochloric acid, potassium phosphate, Tris, ethylenediaminetetraacetic
acid (EDTA), urea, potassium chloride, sodium borate, PVDF membrane, sodium
diethyldithiocarbamate (DDC), phenylmethanesulphonylfluoride (PMSF), Pepstatin
A, Leupeptin, Luria-Bertani (LB) (Miller) broth/agar, ampicillin HCl, sodium
dodecylsulfate (SDS), glycine, TEMED, acetic acid, methanol, brilliant blue R-250,
and a Sonic Dismembrator 500 were purchased from Fisher Scientific. 2-
phenylhydrazine, antipain, lysozyme, DNase, RNase, potassium acetate, horse radish
peroxidase (HRP), 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS),
30% hydrogen peroxide, 2-phenylethylamine, 2-hydrazinopyridine hydrochloride, 4-
nitrophenylhydrazine, copper sulfate (CuSO4) and ethylenediamine were purchased
from Sigma Aldrich.  CAPS, 85% glycerol, potassium pyrophosphate, and isopropyl
#-D-1-thiogalactopyranoside (IPTG) were purchased from Acros.  The BCA assay
kit, Slide-A-Lyzer cassette, and SnakeSkin dialysis tubing were purchased from
Thermo Scientific Pierce Protein Research Products.  TOYO PEARL HW55-F size
exclusion resin, TOYO PEARL DEAE 650-M anion exchange resin, and TOYO
PEARL Butyl 650-M hydrophobicity resin were purchased from Tosoh Bioscience.
Ammonium persulfate, 30% acrylamide/bis solution, and chelex were purchased from
Bio-Rad Laboratories. Open column chromatography was done with an Econo pump
EP-1, an Econo UV monitor EM-1, and a BioLogic BioFrac Fraction collector (Bio-
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Rad).  FPLC chromatography was done with an AKTA FPLC, a HiPrep 16/10 Butyl
FF column, and HiLoad 16/60 Superdex 200 sizing column purchased from GE
Healthcare (Amersham Biosciences).  The FPLC DEAE column was manually
packed into a XK 16/40 jacketed column (GE Healthcare).  Ethanol was purchased
from Decon.  The Amicon Ultra 30K MW cutoff concentrators were purchased from
Millipore.  Nitro blue tetrazolium (NBT) used for quinone staining was purchased
from CalBiochem.  Synthetic oligonucleotides were purchased from Operon
Biotechnologies, Inc.  PCR was performed on a DNA Engine PTC-200 Peltier
Thermal Cycler (Biorad).  Plasmids were prepared using a QIAprep Spin Miniprep
kit (Qiagen).  DNA sequencing was performed at the UC Berkeley DNA sequencing
facility.
Site-directed Mutagenesis.
The expression plasmids for D298K-, M602K-, Y384K-, D298C-, and Y284A-
AGAO were generated by site-directed mutagenesis using a Quikchange mutagenesis
kit from Stratagene on pPEAO-0229 as a parent vector.  The DNA primers used for
D298K were 5(-CCTGGCAGAACTACTTCAAGACGGGGGAGTACCTGGTG-3(
(forward) and 5(-CACCAGGTACTCCCCCGTCTTGAAGTAGTTCTGCCAGG-3(
(reverse) (underlined nucleotides correspond to the sites of mutation).  The DNA
p r i m e r s  u s e d  f o r  M 6 0 2 K  w e r e  5 ( -
GGACTGGCCCATCAAACCGGTGGACACCGTC-3(  ( forward)  and 5(-
GACGGTGTCCACCGGTTTGATGGGCCAGTCC-3( (reverse).  The DNA primers
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f o r  Y 3 8 4 K  w e r e  5 ( -
CCACTATCGGCAACTACGACAAAGGCTTCTACTGGTACCTCTAC-3(
( f o r w a r d )  a n d  5(-
GTAGAGGTACCAGTAGAAGCCTTTGTCGTAGTTGCCGATAGTGG-3(
( r eve r se ) .   The  DNA pr imer s  fo r  D298C were  5(-
CTGGCAGAACTACTTCTGCACGGGGGAGTACCTG-3( (forward) and 5(-
CAGGTACTCCCCCGTGCAGAAGTAGTTCTGCCAG-3( (reverse). The DNA
primers for Y284A were 5(-GATGGTGGTGCCGGCGGGCGATCCGTCCC-3(
(forward) and 5(-GGGACGGATCGCCCGCCGGCACCACCATC-3( (reverse).  The
DNA primers for D298A were 5(-AGAACTACTTCGCTACGGGGGAGTACCTG-
3 ( (forward) and 5(-CAGGTACTCCCCCGTAGCGAAGTAGTTCT-3( (reverse).
An expression plasmid for the double mutant, Y284F/D298K was generated from the
D298K-AGAO expression vector using the DNA primers, 5(-
GATGGTGGTGCCGTTCGGCGATCCGTCC-3(  ( f o r w a r d )  a n d  5 ( -
GGACGGATCGCCGAACGGCACCACCATC-3( (reverse).  The double mutants of
Y284F/M602K and Y284F/Y384K were also prepared from the M602K- and Y384K-
AGAO expression vectors using the Y284F primers seen above.  All plasmids were
fully sequenced and the point mutations were confirmed.  Plasmids were grown in E.
coli DH5) cells and purified using high-speed plasmid mini- and midi-prep kits from
Qiagen.
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Enzyme Expression and Purification.
Wild-type (WT) and mutant AGAO expression plasmids were transformed
into E. coli BL21(DE3) or CD03, a mutant strain of E. coli BL21(DE3) where two
out of three catalase genes were disrupted.12 The mature forms the of WT, D298K,
M602K, Y384K, Y284F/D298K, and Y284F/M602K enzymes were produced by
growing the transformants in LB-ampicillin media at 37°C and induced with 0.1 mM
IPTG and 50 µM Cu2+ at an OD600 between 0.6 and 0.8.  The precursor form of
D298C was produced by growing the transformants in LB-ampicillin media at 37°C
and induced with 0.1 mM IPTG at an OD600 between 0.6 and 0.8.  Expression was
allowed to continue overnight at 26°C.   The cells were harvested by centrifugation at
3,000 x g, 4°C, for 15 min and stored at -80°C until use. The enzymes were purified
to homogeneity following the published procedure.86 All steps of this procedure were
completed at 4°C unless otherwise noted.  Cells were thawed in 30 mM KPi with 10
µM CuSO4 at a final volume of 500 mL. 500 µL 1000x protease inhibitors:  PMSF,
antipain, pepstatin A, and leupeptin were added along with 500 µL 1000x DNase and
RNase.  Small amounts of lysozyme were also added.  Disruption of the cells was
achieved by sonication at an amplitude of 60%.  Cycles of one sec on/one sec off for
one min were repeated every five min for a total of five cycles.  The cells were
centrifuged at 57,000 x g for 1 hr.  The supernatant was mixed with 1 M acetate
buffer pH 5.0 (10% v/v).  This mixture was stirred 20 min and centrifuged 20 min at
12,000 x g.  The pH of the supernatant was adjusted to 6.5 with KOH. (NH4)2SO4
(45% saturated) was added and allowed to stir for 20 min followed by centrifugation
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at 12,000 x g for 20 min.  The pellet was collected and dissolved in a minimal amount
of 20 mM KPi pH 6.5 with 10 µM CuSO4. The sample was dialyzed against 1 L of
this same buffer with 50 mM KCl three times (1 hr, 1 hr, overnight).
The sample was removed from dialysis and centrifuged at 57,000 x g for 20
min before being loaded onto a pre-equilibrated 100 mL DEAE column connected to
a peristaltic pump and UV detector at 4 mL/min. The column was washed with 225
mL of the pre-equilibration buffer (20 mM KPi pH 6.5 with 10 µM CuSO4 and 50
mM KCl).  The protein was then eluted with a four column volume gradient
containing 50 to 200 mM KCl in buffer.  Fractions were collected every 1.0 min.  The
column was washed with three column volumes 200 mM KCl in buffer and re-
equilibrated in three column volumes 50 mM KCl in buffer.  SDS-PAGE gels were
run on every fourth fraction, along with activity assays for CAO and catalase.
Fractions containing active CAO protein were pooled. (NH4)2SO4 (70% saturated)
was added and the mixture was stirred for 20 min.  After 20 min of centrifugation at
12,000 x g, the pellet was dissolved in a minimal amount of 20 mM KPi pH 6.5 with
10 µM CuSO4 and 50 mM KCl and dialyzed against 1 L of the same buffer three
times (1 hr, 1 hr, overnight).
The dialysis product was loaded onto the DEAE column, and the column was
washed with 100 mL of 20 mM KPi pH 6.5 with 10 µM CuSO4 and 50 mM KCl.
The column was further washed with 250 mL of 20 mM KPi pH 6.5 with 10 µM
CuSO4 and 90 mM KCl and the protein was eluted with a four column volume
gradient of 90 to 200 mM KCl in buffer. SDS-PAGE gels were run on every fourth
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fraction along with activity assays for CAO and catalase.  Fractions containing active
CAO protein were pooled and (NH4)2SO4 was slowly added, with stirring, to a final
concentration of 20%.
Pooled protein was loaded onto a pre-equilibrated 50 mL Butyl column.  The
column was washed with 250 mL of equilibration buffer (50 mM KPi pH 6.5 with 10
µM CuSO4 and 20% sat. (NH4)2SO4).  The protein was eluted with an eight column
volume gradient from 20 to 0% (NH4)2SO4 in buffer. SDS-PAGE gels were run on
every third fraction along with activity assays for CAO and catalase.  Fractions
containing active CAO protein and lacking catalase activity were pooled and
concentrated in a spin column, or by adding (NH4)2SO4 to a concentration of 70%,
and dialyzing the sample into 20 mM KPi pH 6.5.  Protein concentrations were
determined by BCA assay.  Protein was stored at -80°C in 50 µL aliquots at 20
mg/mL containing 25% glycerol as a cryoprotectant.  The Y284F/D298K mutant was
not very stable and the purification was performed in the minimal time (2 ~ 3 days).
The precursor forms of WT, D298K, and Y284F/D298K were optimally
expressed using the following procedure:  After transformation, the cells were plated
on LB-ampicillin agar plates and allowed to incubate at 37°C overnight.  A colony
was picked the following morning and added to a 125 mL of LB-ampicillin media
(starter culture) and grown at 37°C, 225 rpm to an OD600 of ~1.4 (~8 hrs). Fifteen mL
of starter culture was used to induce 1.5 L of LB-ampicillin media, which was grown
at 37°C to an OD600 of 0.6-0.8 (~3.5 hrs).  The culture was placed on ice for 15 min
and then induced with 0.1 mM IPTG.  The culture was returned to the shaker and
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grown overnight at 26°C, 225 rpm. The cells were harvested by centrifugation at
3,000 x g, 4°C, for 15 min and stored at -80°C until use.
The purification procedure was modified from a procedure described
previously.29,12 All steps of this procedure were completed at 4°C unless otherwise
noted.  All buffers were chelexed.  The cells were thawed at room temperature in 10
mM HEPES pH 6.8 with 1 mM EDTA and 1 mM DDC to a final volume of 300 mL.
300 µL of 1000x protease inhibitors:  PMSF, antipain, pepstatin A, and leupeptin
were added along with 300 µL of 1000x DNase and RNase.  Small amounts of
lysozyme were also added. Disruption of the cells was achieved by sonication at an
amplitude of 70%.  Cycles of one sec on/one sec off for one min were repeated every
five min for a total of five cycles.  The cells were centrifuged at 57,000 x g for 1 hr.
The supernatant was mixed with 1 M acetate buffer pH 5.0 (10% v/v).  This mixture
was stirred 20 min and centrifuged 20 min at 57,000 x g.  The pH of the supernatant
was adjusted to 6.8 with KOH. (NH4)2SO4 was added to 45% saturated and allowed to
stir for 20 min followed by centrifugation at 57,000 or 12,000 x g for 20 min.  The
pellet was collected and dissolved in a minimal amount of 10 mM HEPES pH 6.8
with 1 mM EDTA and 1 mM DDC.  The sample was dialyzed against 1 L of the same
buffer three times (1 hr, 1 hr, overnight).
The sample was removed from dialysis and centrifuged at 57,000 x g for 20
min before being loaded, at 4 mL/min, onto a pre-equilibrated 250 mL DEAE column
connected to a peristaltic pump and UV detector. The column was washed with two
column volumes of the pre-equilibration buffer (10 mM HEPES pH 6.8 with 1 mM
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EDTA and 1 mM DDC).  The protein was then eluted with a four column volume
gradient containing 100-300 mM KCl in pre-equilibration buffer. Fractions were
collected every 1.5 min. SDS-PAGE was run on every third fraction and fractions
containing CAO were pooled. (NH4)2SO4 was added to 70% saturated and the mixture
was stirred 20 min.  After 20 min of centrifugation at 57,000 or 12,000 x g the pellet
was dissolved in a minimal amount of 10 mM HEPES pH 6.8 with 1 mM EDTA and
1 mM DDC and dialyzed against 1 L of the same buffer three times (1 hr, 1 hr,
overnight).
The sample was removed from dialysis and centrifuged at 57,000 x g for 20
min before being loaded onto a pre-equilibrated 80 mL DEAE FPLC column.  (Buffer
A: 10 mM HEPES pH 6.8 with 1 mM EDTA and 1 mM DDC).  The column was
washed with two column volumes of the buffer with 5 % buffer B (Buffer A + 1 M
KCl).  The protein was eluted with an eight column volume gradient from 5-30%
buffer B.  The column was washed with one column volume of 40% buffer B
followed by two column volumes of 50% buffer B and two column volumes of H2O.
The column was re-equilibrated in 10 mM MES pH 5.8 with 1 mM EDTA and 1 mM
DDC.  An SDS-PAGE gel was run on every third fraction and fractions containing
CAO were pooled.  Pooled fractions were precipitated by adding (NH4)2SO4 to 70%
saturated and stirring 20 min. After 20 min of centrifugation at 57,000 or 12,000 x g
the pellet was dissolved in a minimal amount of 10 mM HEPES pH 6.8 with 1 mM
EDTA and 1 mM DDC and dialyzed against 1 L of the same buffer three times (1 hr,
1 hr, overnight).
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The sample was removed from dialysis and (NH4)2SO4 was added to 25%
saturated.  The sample was stirred 20 min and centrifuged 20 min at 57,000 x g.  Half
of the sample was loaded onto a pre-equilibrated 20 mL Butyl FPLC column  (Buffer
B: 10 mM HEPES pH 6.8 with 1 mM EDTA, 1 mM DDC and 25% saturated
(NH4)2SO4).  The column was washed with two column volumes of 75% buffer B and
the protein was eluted with a seven column gradient from 75-20% buffer B.  The
column was washed with two column volumes of buffer A (buffer B without
(NH4)2SO4), re-equilibrated, and the same method was run on the other half of the
sample. An SDS-PAGE gel was run on every third fraction, and fractions containing
CAO were pooled.  Pooled fractions were precipitated by adding (NH4)2SO4 to 70%
saturated and stirring 20 min. After 20 min of centrifugation at 57,000 or 12,000 x g,
the pellet was dissolved in a minimal amount of 10 mM MES pH 5.8 with 1 mM
EDTA and 1 mM DDC and dialyzed against 1 L of the same buffer three times (1 hr,
1 hr, overnight).
The sample was removed from dialysis and centrifuged at 57,000 x g for 20
min before being loaded onto a pre-equilibrated 80 mL DEAE FPLC column.  (Buffer
A: 10 mM MES pH 5.8 with 1 mM EDTA and 1 mM DDC).  The column was
washed with two column volumes of the buffer with 10% buffer B (Buffer A + 1 M
KCl).  The protein was eluted with a seven column volume gradient from 10-35%
buffer B. An SDS-PAGE gel was run on every third fraction, and fractions containing
CAO were pooled.  Pooled fractions were concentrated in a spin column to about two
mL.  An additional FPLC sizing column was run on D298A samples being purified
36
for crystallography using 10 mM HEPES pH 6.8 with 1 mM EDTA and 1 mM DDC.
All protein samples were dialyzed in a spin column into 10 mM HEPES pH 6.8 (5 x
15 mL).  Protein concentrations were determined spectrophotometrically by using
extinction coefficients at 280 nm of 12.3 and 13.2 for 1% (w/v) solutions of the apo
and holo forms of AGAO, respectively.29 Protein not being used immediately was
stored at -80°C in 40 mg/mL aliquots containing 25% glycerol as a cryoprotectant.
Activity Assay
The holo enzyme activity was assayed by one of two methods.  The first
method measures the production of hydrogen peroxide using horseradish peroxidase
(HRP)–2,2’-azino-bis(3-ethyl)-benzthiazoline-6-sulfonic acid (ABTS) coupled assay,
according to published procedure.29,44,87 In this assay, CAO produces H2O2, which acts
as a substrate for HRP to give an activated form.  The activated HRP oxidizes ABTS
to give a &max of 414 nm.  UV/vis spectroscopy was performed on a Shimadzu UV-
2501 PC dual beam UV/vis spectrophotometer equipped with a temperature-
controlled cell holder at 30 ± 0.2 °C (path length of 1 cm).  A 5 mL stock solution of
50 mM KPi pH 7.2, 2.5 µL of 10 mg/mL HRP, and 250 µL of 20 mM ABTS was
made.  100 µL of the stock solution was placed in a 100 µL cuvette followed by 1 µL
of 10 mM 2-phenylethylamine and a variable amount of enzyme of known
concentration.  The absorbance at 414 nm was observed with a cycling time of 0.2 sec
for a total of 240 sec.  The activity was calculated from the change in absorbance
between 30-120 sec.
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The second method was to measure the amount of O2 consumed using a Clark
type polarographic electrode (Hansatech Instruments) using 2-phenylethylamine as a
substrate with variations from the published procedure.12,29 The temperature of the
reaction was maintained at 30°C with the use of a circulating water bath. The
chamber of an O2 electrode was filled with 500 µL of 50 mM KPi pH 6.5 and 50 µL
of 5 mM 2-phenylethylamine.  The reaction was started with the addition of a
variable amount of enzyme of known concentration.
The redox activity of holo D298C was determined by adding two equivalents
of NaIO4 (1 µL) to the 70 µL of 0.128 mM sample after biogenesis.  Spectra were
taken every 30 sec for 10 min.  The reaction was incubated at room temperature
overnight and an additional spectrum was taken.  An equal volume of 12 M urea was
added and the sample was heated at 30°C 1.5 hrs followed by heating at 50°C 1 hr.
The reaction was monitored by UV/vis.
Catalase activity was measured by an ABTS coupled assay with hydrogen
peroxide as the substrate. UV/vis spectroscopy was performed on a Shimadzu UV-
2501 PC dual beam UV/vis spectrophotometer equipped with a temperature-
controlled cell holder at 30 ± 0.2 °C (path length of 1 cm).  A 10 mL stock solution of
0.1 M KPi pH 6.5 with 10 µL of 1 M H2O2 and 500 µL of 20 mM ABTS was
prepared. A stock solution of 100 µL was placed in a 100 µL cuvette followed by 5
µL of enzyme of unknown concentration. The absorbance at 414 nm was observed
with a cycling time of 0.2 sec for a total of 240 sec.  The activity was calculated from
the change in absorbance between 30-120 sec.
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Phenylhydrazine Titration
A phenylhydrazine titration was preformed after protein purification in order
to determine the amount of active TPQ in the sample.  The experiment was conducted
on a monochromator type UV-vis equipped with a thermostatted cell chamber set to
30°C.  A known concentration (5 µM subunit for WT) of enzyme in 20 mM KPi pH
6.5 was added to a 500 µL cuvette. Phenylhydrazine was added in 2.5 µL aliquots
containing 0.025 to 0.1 equivalents.  Spectra were taken until no further change in
absorbance at 438 nm was observed. Aliquots of phenylhydrazine were added in this
manner until addition of phenylhydrazine no longer produced a change in absorbance
at 438 nm.
Quinone Staining
The presence of a quinone in WT and mutants of CAO was determined by the
standard quinone-staining method.88 An SDS-PAGE gel was run on the samples,
which were transferred to a PVDF membrane.  The membrane was rinsed three times
with water before covering the membrane in 2 M potassium glycinate pH 10.0 with a
few milligrams of NBT.  The membrane was allowed to shake in the solution, in the
dark, for 45 min.  The membrane was then rinsed with 0.1 M sodium borate
(Na2B4O7) pH 10.0.  The membrane was dried between paper towels in the dark.
ICP Analysis
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Inductively coupled plasma (ICP) analysis was done by StatAnalysis Corp. on
holo samples of WT (7.14 mg/mL), D298K (7.14 mg/mL), Y284F/D298K (11.16 and
11.7 mg/mL), and M602K (8.33 mg/mL) in order to quantify the amount of Cu2+ in
each of the samples.  Samples were dialyzed into 20 mM KPi buffer at pH 6.5 with 1
mM EDTA to remove excess Cu2+ followed by dialysis into the same buffer without
EDTA.
Reaction with 2-Hydrazinopyridine, 4-Nitrophenylhydrazine and Ethylenediamine.
In order to determine the reactivity of the enzyme samples with inhibitors,
enzyme solutions of 10 µL of 20 mg/mL WT, D298K, or M602K samples were
added to 90 µL of 20 mM KPi pH 6.5 with 10 µM CuSO4 and 5 µM KCl or 20 mM
Tris pH 7.8, followed by 2 µL of 7 mM (five molar equivalents) of the hydrazine or
ethylenediamine.  The mixture was incubated at 30 °C and the absorption spectra was
taken on a Shimadzu UV-2501 PC dual beam UV/vis spectrophotometer equipped
with a temperature-controlled cell holder at 30 ± 0.2°C.  In some cases, the
temperature of the reaction was increased to 60°C and the sample was incubated 30
min and 3 hrs before spectra were taken.
Reaction with Urea
Enzyme solutions of holo WT and D298K CAO were dialyzed in a slide-a-
lyzer into 20 mM Tris pH 7.8 with 1 mM EDTA or 0.1 M KPi pH 6.8 with 1 mM
EDTA, then was dialyzed again without EDTA.  The enzyme solution was then
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dialyzed in an Amicon concentrator into buffer with 2, 6, 8 or 9 M urea in order to
disrupt the hydrogen bonding interactions within the active site of CAO.
Alternatively, an equal volume (35 µL) of enzyme solution and 12 M urea were
combined for a final concentration of 20 mg/mL enzyme in 6 M urea.  UV/vis
spectroscopy was performed on a Shimadzu UV-2501 PC dual beam UV/vis
spectrophotometer equipped with a temperature-controlled cell holder at 30 ± 0.2 °C
(path length of 1 cm).   Following the reaction with 12 M urea, samples were further
reacted with five molar equivalents 2-hydrazinopyridine or 4-nitrophenylhydrazine
(1.4 µL 70 mM stock solution).  The reactions were monitored by UV/vis for one
hour.
pH Jump
In order to determine if the LTI cofactor is sensitive to alkaline hydrolysis,
holo D298K CAO samples were dialyzed into 0.1 M KPi pH 6.5 to remove excess
Cu2+.  The pH of the samples was adjusted either by overnight dialysis into 20 mM
K2CO3 pH 10, dialysis in a spin column into 110 mM pyrophosphate (PPi) buffer pH
9.5, or by the addition of 90 µL of 1 or 2 M KOH to 10 µL of 20 mg/mL enzyme
sample.  WT and M602K samples at pH 6.5 and 9.5 were reacted with one equivalent
2-hydrazinopyridine and spectra were taken at 10 and 20 min after incubation of the
sample at room temperature.  Holo WT and M602K samples were reacted with
phenylhydrazine followed by the addition of KOH or HCl.  A sample of 100 µL of 2
mg/mL WT or M602K was reacted with 2 µL of 7 mM phenylhydrazine (5 molar
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equivalents), and the reaction was monitored by UV/vis for one hour.  The excess
phenylhydrazine was removed by dialysis against 1 L of 20 mM KPi pH 6.5 for 1 hr
and again overnight.  To half the sample was added 4 M KOH or 2 M HCl and the
product was observed by UV/vis. UV/vis spectroscopy was performed on a Shimadzu
UV-2501 PC dual beam UV/vis spectrophotometer equipped with a temperature-
controlled cell holder at 30 ± 0.2 °C (path length of 1 cm).
UV/vis Biogenesis Study
The biogenesis study of WT and D298K was performed as previously
described for WT.29,68 The biogenesis of WT and D298K was monitored by UV/vis
spectroscopy on an Agilent HP 8453 photo diode array UV/vis spectrophotometer
equipped with a temperature-controlled cell holder at 30 ± 0.2 °C (path length of 1
cm). The spike in the spectra at 483 nm is an artifact of the instrument. Protein
samples (25-50 µL) were dialyzed in an Amicon concentrator five times against 500
µL of 100 mM HEPES pH 6.8.  D298K biogenesis reactions were carried out in the
presence of water saturated O2 or air.  For samples run in concentrated O2 conditions,
a 50 µL sample of 0.2 mM protein was added to a cuvette, which was fitted with a T-
shaped connector.  A balloon was attached to the connector at a right angle to the
cuvette, and a septum was used to seal the connector from the top (in line with the
cuvette).  The cuvette was purged with O2 bubbled through water for 15 min.  Care
was taken to ensure that the sample was not bubbled.  The balloon was allowed to fill,
followed by the addition of 50 µL O2 purged 1 mM CuSO4 directly into the sample
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through the septa in line with the cuvette.  The instrument was blanked with water.
The sample was mixed quickly and placed into the instrument.  Spectra were taken
every 10 sec for 10 min, followed by spectra taken every 2 min for 50 min and every
10 min for 1 hr for the D298K samples.  The spectra for the WT samples were taken
every 10 sec for 10 min and every 1 min for 20 min in air.  The reaction was run in air
without the balloon fitting or water saturation.  D298K samples were run in air with 1
mM CuSO4.  The rates of formation of the 500-nm and 454-nm chromophores were
determined spectrophotometrically in a reaction mixture containing 0.1 mM apo-
D298K and 0.5 mM CuSO4 in 50 mM buffer at pH 6.8.  The final concentrations of
enzyme were determined spectrophotometrically by using extinction coefficients at
280 nm of 13.2 for 1% (w/v) solutions of the holo form of AGAO.29
The biogenesis of apo D298C was done by adding 37.5 µL of 1 mM CuSO4 to
37.5 µL of 0.063 mM D298C in 10 mM HEPES pH 6.8.  The sample was incubated
at room temperature two days before taking a spectrum.  Alternatively, 37.5 µL of 1
mM CuSO4 was added to 37.5 µL of 0.255 mM D298C in 10 mM HEPES pH 6.8.
The sample was mixed rapidly and placed in a cuvette.  UV/vis spectra were taken
every 30 sec for 10 min, every 5 min for 50 min, and every 1 hr overnight.
43
Results
Expression and Purification of Wild-type and Mutant AGAOs
Each method of protein expression yielded approximately 105-110 g of wet E.
coli cells.  However, the amount of protein recovered varied based on mutant, growth
conditions, and purification method.  Although yields varied, mutants behaved the
same as WT during expression and purification.  Table 2.1 shows a summary of the
yields. The purity of the samples was ~99% as estimated from SDS-PAGE gels.
UV/vis Spectroscopic Properties of Holo-D298K and Holo-M602K.
Figure 2.5 shows the UV/vis absorption spectra of D298K, M602K and WT.
The purified holo-D298K and holo-M602K were yellowish brown, which contrasts
with the characteristic pink color of WT-AGAO.  WT shows a typical broad
absorbance with a &max at 476 nm.
12 At physiological pH, the TPQ cofactor exists as a
resonance stabilized mono-anion where the 4-hydroxyl group is deprotonated.7 The
&max of the WT-AGAO reflects the extent of resonance delocalization of the O4 oxo-
Table 2.1 Protein yields for holo protein growth and purification conditions and
for optimized apo protein growth and purification conditions. * not optimized






anion of the TPQ cofactor. The O4 of TPQ is in hydrogen bonding contact with the
conserved Tyr284, and O2 of TPQ is in hydrogen bonding contact with two water
molecules.  D298K and M602K have a &max at ~450 nm that is ~30 nm blue-shifted
from that of WT-AGAO.  A similar 30 nm blue-shift in &max has been seen for the
TPQ cofactor in D298A-AGAO46 and also in D383A-ECAO15 where, in these
mutants, it is likely a result of the partial localization of electrons at O4 of TPQ.  In
the D298A-AGAO crystal structure,46 the distance between O4 and the hydroxyl
group of Tyr284 is a little shorter (2.3 Å) than that seen in the WT structure (2.5 Å),
consistent with a localization of the charge at O4.12 In addition to the absorbance at
450 nm, D298K also contains a prominent strong absorbance at 320 nm that is absent
in WT, D298A and M602K.  Such a band has been seen for LOX isolated from
bovine aorta89 as well as a recombinant form of LOX-like protein from Drosophila
Figure 2.5 UV/vis absorption spectra of D298K, M602K, D298A, and WT-
AGAO. Spectra are normalized to ~0.1 mM and were run in 50 mM HEPES











































melanogaster.2 These observations suggested that the blue-shift in the visible
spectrum of D298K might not simply be due to a change in charge distribution in the
TPQ cofactor.
Reactivity of D298K and M602K towards Amine Substrate and Hydrazine Inhibitors.
The UV/vis spectra of D298K and M602K indicated the presence of a quinone
that is different from TPQ in WT.  The presence of a quinone in these mutants was
determined by the standard quinone-staining method (Figure 2.6).88 Both D298K and
M602K were positive for quinone staining although staining was significantly weaker
than WT.
The TPQ cofactor in CAO forms an intense chromophore with hydrazines and
the chromophore formation has been used to titrate the amount of TPQ in CAOs.90 In
WT-AGAO, TPQ can be converted to hydrazone-azo derivatives with
Figure 2.6 SDS-PAGE gels and PVDF-membranes stained for quinone detection.
a) Lane 1: Kaleidoscope molecular marker, lane 2: WT-AGAO, lane 3: D298K-
AGAO, lane 4: molecular marker, b) lane 1: Kaleidoscope molecular marker, lane
2:  M602K, lane 3: WT, lane 4: molecular marker
a b
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phenylhydrazine,12 2-hydrazinopyridine56 or 4-nitrophenylhydrazine.29 M602K
reacted with phenylhydrazine, and the titration indicated that the protein sample
contained 40% active quinone (a typical result for WT is 65% titratable) (Figure 2.7).
Consistent with the presence of a reactive quinone, M602K showed 0.45% activity
towards 2-phenylethylamine in comparison to WT using a Clark O2 electrode to assay
O2 consumption.  The resonance Raman spectrum of the phenylhydrazine-derivatized
M602K was very similar to that of the TPQ-phenylhydrazone adduct (Figure 2.8).
This clearly indicated that the quinone in M602K is TPQ and that no cross-link had
occurred between the !-amino side chain of Lys602 and dopaquinone.  For this
reason, we did not pursue further characterization of M602K.
In contrast to M602K and WT, the quinone in D298K did not react with any
of the hydrazines; no spectral change was observed even after prolonged
Figure 2.7 Phenylhydrazine titration of M602K.  Phenylhydrazine was added in
0.1 equivalents.  Final spectra were taken after 15 min for each equivalent.  Insert















































 incubation.  D298K also showed no activity towards oxidative deamination of 2-
phenylethylamine.  This showed that the quinone formed in D298K was trapped in a
Figure 2.8 Resonance Raman spectrum of phenylhydrazine adducts. a)
Arthrobacter P1 amine oxidase (AGAO), b) E. coli K-12 amine oxidase (ECAO),
c) 3,4,6-trihydroxyphenylalanine quinone (TOPA),6 and d) M602K AGAO.
Panals a-c were reproduced with permission from Cooper, R. A.; Knowles, P. F.;
Brown, D. E.; McGuirl, M. A.; Dooley, D. M., 1992, Biochemical Journal 288,






conformation that could not react with amines.  The crystal structure of D298K shows
LTI in the flipped conformation, with the C5 carbonyl group facing away from the
proposed substrate entry channel.  In agreement with these data, D298K is not active
towards oxidative deamination of substrate amine and does not react with inhibitors
such as 4-nitrophenylhydrazine and 2-hydrazinopyridine.  The combination of UV/vis
and resonance Raman spectroscopies (shown below) and the structural data suggested
that D298K contains a quinone other than TPQ.  ICP analysis of the Cu2+ content in
D298K indicated that the species contained ~75% Cu2+ while WT contained ~72%.
Comparison of UV/vis Spectra of D298K with LTQ and LTI Model Compounds
Figure 2.9 shows the UV/vis spectra of an LTQ model compound, 5-tert-
butyl-4-N-n-butylamino-1,2-benzoquinone at pH 7 and pH 11 (see Scheme 2.2).  At
physiological pH, the model compound is stabilized as an ortho-quinone with &max at
504 nm as seen in LTQ in LOX.91 The pKa of the amino group of the n-butylamino
side chain of the related model compound, 5-ethyl-4-N -n-butylamino-1,2-
benzoquinone, has been determined to be 10.3 by UV/vis spectroscopic pH titration.1
5-tert-Butyl-4-N-n-butylamino-1,2-benzoquinone92 was used in this study as the 5-
ethyl-quinone was not stable in alkaline conditions.  Upon deprotonation, a 50-nm
blue-shift in &max was observed due to the formation of the monoanionic form of LTI
(Scheme 2.2). The monoanionic form of LTI resembles the chromophore in D298K
(Figure 2.5) although it lacks the large absorption around 320 nm.  Nonetheless, the
visible spectrum of D298K is similar to that of the monoanionic LTI, supporting the
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tentative assignment of the quinone in D298K as the iminoquinone tautomer of LTQ.
The differences in the UV spectrum between D298K and the model compound may
arise from the difference in protonation states, where the quinone in D298K would be

















Figure 2.9 UV-vis spectra of LTQ and LTI (mono-anionic form) model
compounds. [LTQ] = 1.7 mM in 50 mM HEPES buffer, pH 6.8; [LTI] = 1.7 mM
in 0.1 M NaOH.— LTQ, ---LTI.




















505 nm 450 nm
50
Effect of pH on the UV/vis Spectrum of D298K.
It has been shown in model studies that the C5 carbonyl group of TPQ
undergoes nucleophilic addition of substrates and inhibitors, whereas the C2 carbonyl
group is unreactive.51 The C2 carbonyl group is less electrophilic than that at C5 due
to the resonance delocalization of the O4 oxoanion at physiological pH.  This
selective reactivity of nucleophiles at C5 of the TPQ cofactor over C2 has also been
confirmed in CAO.35 In addition to the resonance effect, the C5 carbonyl group is
located near the proposed substrate entry channel9 and the active site base, Asp298,
for optimal activity.  For this reason, it is less likely that the C2 carbonyl group of the
TPQ cofactor reacts with the !-amino side chain of Lys298 to form LTI in D298K.
Alternatively, it could be possible that TPQ is formed initially in D298K, but the C5
carbonyl group of TPQ reacted with !-amino side chain of Lys298 to form an
iminoquinone similar to the substrate Schiff base intermediate in the catalytic
cycle.35,51 If so, the C5 imino group should be sensitive towards alkaline hydrolysis.
To test for this possibility, D298K was incubated in pH 10 buffer.  Under these
conditions, we did not see any red-shift of &max to 480 nm, suggesting that the
hydrolysis to TPQ did not occur.  This is consistent with the cross-link between the !-
amino side chain of Lys298 and the quinone being at the C2 position, as revealed by
the X-ray crystal structure.  However, when D298K was reacted with 1 M KOH for 1
min a red shift of ~30 nm was observed.  Additionally, peaks around 340 and 370 nm
were observed (Figure 2.10).  The peak at 510 nm is like that seen in the model
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compound of LTQ as well as LOX isolated from bovine aorta89 and a recombinant
form of LOX-like protein from Drosophila melanogaster.2
Effect of Disrupting the Hydrogen Bonding Interaction between O4 and Tyr284 on
the UV/vis Spectrum of D298K.
The X-ray crystal structure of D298K (Figure 2.11) suggested a strong
hydrogen bonding interaction (2.4 Å) between O4 of the quinone and the conserved
Tyr284 (Scheme 2.1).  In order to assess whether this hydrogen bonding interaction
contributes to stabilizing the LTI tautomer in D298K, we disrupted the interaction by
denaturation with 8 M urea at pH 7. The denaturation yielded a drastic spectral
change to form a large absorbance around 350 nm but almost no absorbance above
Figure 2.10  UV/vis spectra of D298K at increased pH. %D298K was slowly
dialyzed into 20 mM K2CO3 pH 10.  The sample was warmed to 30°C and the
spectrum was taken after 1 hr.  The final concentration of enzyme was normalized
to ~0.056 mM.  %D298K was reacted with 1 M KOH.  The spectrum was taken


















Figure 2.12 UV/vis spectrum of D298K in urea. 0.28 mM D298K in 0.1 M KPi


















Figure 2.11 Hydrogen bonding interaction stabilizing the LTQ-like quinone as the












 450 nm (Figure 2.12).  Interestingly, a very similar spectral change was observed
upon copper removal from LOX isolated from bovine aorta in 6M urea where the 350
nm species was proposed to be derived from a covalent modification of the LTQ with
an amino acid side chain.89 It could be possible that the similar modification took
place on the LTQ-like quinone in denatured D298K.
In order to define the role of the hydrogen bond between Tyr284 and the O4
of the quinone in D298K in stabilizing LTI over LTQ, we prepared a double mutant
Y284F/D298K.  The yields for the double mutants are shown in Table 2.2.  The
Y284F/D298K double mutant was positive for quinone-staining (Figure 2.13) but did
Protein yields (mg/mL) Holo protein
Y284F/D298K 0.667
Y284F/M602K 1.764
Table 2.2 Protein yields for double mutant holo protein growth and purification
conditions.





Figure 2.13  SDS-PAGE gel and PVDF-membranes of Y284F/D298K a) 10 %
SDS-PAGE gel and b) PVDF-membrane stained for quinone detection. Lane 1:
Kaleidoscope molecular marker, lane 2: Y284F/D298K-AGAO, lane 3: molecular
marker.
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not react with phenylethylamine and hydrazines as in the case of D298K.  This was
predicted as the quinone had been fixed in the inactive orientation due to the cross-
link; therefore, the active carbonyl group at C5 is not accessible by nucleophiles. The
UV/vis spectrum of Y284F/D298K has a broad absorbance at 504 nm very similar to
the LTQ cofactor (Figure 2.14).1 This red-shift compared to the quinone in D298K
would be expected if the LTQ tautomer dominated the equilibrium. Further
characterization of this mutant was not possible due to the instability of the quinone,
which readily formed a 350 nm species similar to that seen in urea denaturation of
D298K discussed above. We were only able to prepare the holo form of the double
mutant by growing host cells (E. coli) in the presence of Cu2+; any attempts to isolate
and reconstitute apo-Y284F/D298K were unsuccessful. The UV/vis spectrum of the
holo-Y284F/D298K was taken immediately after purification. These results suggest
that the quinone in D298K is stabilized as LTI through a hydrogen bonding
Figure 2.14 UV/vis spectra of an LTQ model compound and Y284F/D298K.
[LTQ] = 1.7 mM, [Y284FD298K] = 0.1 mM in 50 mM HEPES buffer, pH 6.8.
—LTQ model — Y284F/D298K.
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interaction with Tyr284 and such an interaction must be absent for the LTQ cofactor
in LOX.
Biogenesis and UV/vis Spectroscopic Properties of D298C
In order to determine if a Cys side chain at D298 position could trap the DPQ
intermediate, the D298C mutant was prepared.  The reaction of apo D298C with
CuSO4 did not appear to produce a quinone from the UV/vis spectrum (Figure 2.15
a). A cysteinyldopa quinone would be expected to show a broad quinone peak around
450 to 500 nm as amino- and indolquinones.1,93,94 This is not unexpected as the
formation of a 1,6-crosslink to DPQ most likely results in a reduced catechol species
as observed in the mechanism of melanin formation.84 In order to determine whether a
catechol species was formed, the reaction product was tested for redox activity by
Figure 2.15 UV/vis spectra of D298C a) —apo D298C and —holo D298C.  Final
concentrations were 0.1 mM D298C, 50 mM HEPES pH 6.8 and 0.5 mM CuSO4
(holo only). The insert shows the difference spectra of holo-apo D298C. b) Holo




















































reacting it with 2 eq. NaIO4 in the presence of 6 M urea (Figure 2.15 b). Again, the
spectral features of a quinone were not observed, indicating that a catechol was also
not formed from the reaction. The increase in absorbance of the holo species in
comparison to the apo species is likely the result of baseline drift due to protein
precipitation.  It is likely that the DPQ is not accessible by the SH of the cysteine or
that DPQ was not formed at all. If DPQ was not formed and the Tyr precursor
remained, there may be some conformational change in the protein by the
incorporation of the cysteine residue. The initial steps of the biogenesis reaction occur
at the copper binding site. The cysteine residue is away from the copper binding site
and should not directly inhibit the initial steps of biogenesis; thus, DPQ should be
formed unless some change in the conformation of the copper binding site occurred.
Further investigation of this mutant was not done.
Biogenesis of LTI in D298K.
In WT-AGAO, the formation of TPQ occurs directly from the Cu2+-bound
tyrosine precursor where no spectroscopic intermediates have been observed.  The
formation of TPQ is rapid and complete within a couple of minutes under saturating
concentrations of O2 at pH 6.8.  The time course of LTI formation in D298K at pH
6.8 was similarly followed by UV/vis spectroscopy (Figure 2.16).  The apo-D298K
was prepared by the standard procedure used to prepare apo-WT.12,29 The apo-D298K
was mixed with a Cu2+ solution at saturating concentrations of O2 (1.1 mM at 30 °C).
The initial reaction did not produce LTI, but instead produced a pink species with a
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broad visible absorbance centered at ~500 nm.  The ~500 nm pink species formed
followed by its absorption slowly decreasing (~4 hours to completion) concomitant
with the increase in absorbances at 454 nm and 320 nm to give a final spectrum that
Figure 2.16 UV/vis spectral changes after addition of Cu2+ to apo-D298K under
O2-saturating conditions ([O2] = 1.1 mM) at 30 °C.  a) First phase: absorption
spectra were recorded at 2.5, 3.5, 4.5, 6.5, 10.5, 15.5, and 20.5 min.  b) Second
phase: absorption spectra were recorded at 30.5, 40.5, 50.5, 60, 70, 80, 90, 100,
110, and 120 min.  Arrows indicate the direction of the spectral changes.  c)
Absorbance changes at 320 (!), 454 ("), 550 nm (!) were plotted against time























































































was identical to that of LTI in holo-D298K described above.  An isosbestic point at
473 nm was observed for the conversion of the ~500 nm species to the 454 nm
species.  The rate constant of formation of the 500-nm species is 0.22 min–1 at pH 6.8
in concentrated O2, and this rate is about 1/6 of that of TPQ biogenesis in WT (1.50
min–1).68 The 500-nm intermediate could be either TPQ, which reacts with the lysine
side-chain to form the cross-link, or it could be an LTQ-like quinone that slowly
converts to the LTI tautomer (Scheme 2.3).  In both of these cases, there is an O2-
dependent step (formation of the 500-nm species) and O2-independent step (formation
of LTI from the 500-nm species).  When the biogenesis reaction was performed at
atmospheric O2 concentrations (225 µM at 30 °C), the rate of formation of the 500-
nm species decreased to 0.05 min–1, but the rate of the formation of LTI was





























































unchanged versus saturated O2 (Table 2.3).  This is consistent with both of the
possible mechanisms for the formation of LTI from the 500-nm species.  If the 500
nm species was an LTQ-like quinine, these results would suggest that the rate-
limiting step in the biogenesis of the 500-nm species in D298K versus TPQ in WT is
the same.  This is consistent with TPQ biogenesis in D298A where the removal of the
carboxyl side chain of Asp298 has only a minimal effect on the rate of biogenesis of
TPQ (40% reduction).46
The 500-nm intermediate is not reactive towards hydrazines, suggesting that it
is not TPQ.  This result rules out the mechanism where the !-amino side chain reacts
with C2 carbonyl of TPQ to form the iminoquinone.  This was expected as the C2
carbonyl of TPQ is intrinsically unreactive.35,51 The cross-link has most likely already
formed in the 500-nm species from the reaction of the amine with dopaquinone.
Based on our observation that the LTI tautomer is stabilized by a hydrogen bonding
interaction with Tyr284, we propose that the slow conversion of the 500-nm species
to LTI is controlled by a subtle conformational change in the active site where LTI is
the thermodynamic product in D298K.
In order to gain further insight into the identity of the 500-nm species
observed at the early stage of the biogenesis, the time course of the biogenesis of the
Table 2.3 Rates of Biogenesis of D298K
[O2] first phase (min
–1
) second phase (min
–1
) 
1.1 mM 0.2212 ± 0.0028 0.0093 ± 0.0005 
225 M 0.050 ± 0.006
 
0.0111 ± 0.004 
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quinone in D298K was followed by resonance Raman spectroscopy ([O2] = 225 µM)
(Figure 2.17).  Under the reaction conditions used for resonance Raman spectroscopy,
the rate of the biogenesis was significantly slower (most likely due to high
concentration of enzyme (1 mM) used where O2 becomes a limiting reagent), but the
overall trends of the spectral change were similar to what was observed in the UV/vis
spectroscopy experiment.  During the initial phase of the biogenesis, peaks at 1186,
1364, 1393, 1554, 1688 cm–1 appeared where these species were associated with the
500-nm species (Figure 2.17).  As the absorbance at ~500 nm decays, the peaks at
1186, 1554, and 1688 cm–1 then disappeared; and therefore, they are likely derived
solely from the 500-nm intermediate.  The peaks observed during the biogenesis at
1364 and 1393 cm–1 are very close in energy to those associated with holo-D298K (at
1361 and 1391 cm–1, Figure 2.17) but the observed ratio of the two peaks is different:
holo, 1361<1391; intermediate, 1364>1393.   One interpretation of the resonance
Raman spectrum at 6 hr (holo-D298K) is that at 514.5 nm we are selectively probing
the 500-nm species over LTI and are therefore observing a small amount of the 500-
nm species that remains in equilibrium with LTI.  This would explain the decrease in
intensity of the features over time course of the reaction.
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Figure 2.18 shows the comparison of D298K-500-nm species (c), holo-
D298K (b) and WT-AGAO (TPQ) (a) in comparison to model compounds of LTQ
(d) and monoanionic LTI (e).  The D298K-500-nm species is clearly neither TPQ nor
LTI, thereby making a biogenesis mechanism where TPQ is an intermediate less
b
a
Figure 2.17 UV/vis and resonance Raman spectra of the time course of D298K
biogenesis.  a) UV-vis spectral change following incubation of apo-D298K (1.25
mM) and Cu2+ (2.5 mM) in 50 mM HEPES buffer at pH 6.8 at 30°C.  b)
Resonance Raman spectral change.  Accumulation time = 1 sec x 100 scans x 1
set at room temperature, references are toluene and acetone.  
Accuracy = ± 1 cm–1
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likely.  The 500-nm species is very similar to the LTQ model compound, but does
have some differences.  Most likely the protein environment is modulating the
electronic structure of the quinone in D298K-500-nm species, thereby making it
difficult to compare directly to LTQ in solution.
































Figure 2.18  Resonance Raman spectra of holo-D298K, the 500-nm intermediate
seen in the biogenesis of D298K, TPQ in WT, LTQ model compound in 50 mM
HEPES, pH 6.8, and mono-anionic form of LTI model compound in 0.1 M KOH.
a) WT (TPQ), b) holo-D298K, c) the 500-nm intermediate, d) LTQ model
compound, e) mono-anionic form of LTI model compound.  Excitation
wavelength = 514.5 nm
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Conclusion
In the present study we were able to effectively trap the DPQ intermediate by
incorporating Lys at the D298 position (D298K). This strongly supports the
intermediacy of DPQ in the biogenesis of TPQ and suggests that DPQ is, likely, also
on the pathway of LTQ formation. The formation of an LTQ-like quinone in D298K
showed that the proposed dopaquinone intermediate (Figure 1.2 b) has mobility and
can leave the Cu2+ site and swing into the active site wedge to react with Lys298.  The
quinone in D298K is in the flipped orientation, making it inactive.  An attempt was
made to trap the dopaquinone with a lysine residue incorporated at position 602 in
AGAO (M602K).  Met602 is on the opposite side of the active site compared to
Asp298 and, should a cross-linked quinone be formed, it would be expected to be in
an active conformation.  However, the holo-M602K contained TPQ where no such
cross-link formed.  The most likely explanation for this is that the lysine (Lys602) is
not accessible to the C2 position of the flipped dopaquinone, and thereby cannot
compete effectively with hydration.  An attempt was also made to trap the
dopaquinone with a cysteine residue in the D298 position.  Cysteine has been known
to add to dopaquinones in a 1,6-addition as opposed to the 1,4-addition in D298K.  In
that study, it appeared that the protein precipitated during biogenesis and a cross-link
was not formed. It is likely that either DPQ was not formed or that the DPQ is not
accessible by the SH group on cysteine.
An important observation from this study is the absence of any detectable
amount of TPQ in D298K.  The active site of AGAO is arranged to optimize the 1,4-
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addition of copper associated water to dopaquinone intermediate to form TPQ.  A
recent model study suggested that an appropriately placed Cu2+ ion can catalyze the
1,4-addition of water to dopaquinone.95 The mutation site to incorporate the lysine
residue in D298K is away from the copper site and it is less likely that the
environment around copper is significantly altered when compared to WT.  The rate
of formation of the 500-nm species is close to that of WT and D298K suggesting that
initial steps of biogenesis, activation of Tyr382 and subsequent oxidation to
dopaquinone, are not perturbed in D298K.  However, in D298K the dopaquinone
intermediate is selectively trapped by the amino group of Lys298 to form LTI.  This
suggests that 1,4-addition of the !-nitrogen of Lys298 to the dopaquinone
intermediate in CAO is much more efficient than the addition of copper associated
water, even though the latter is the natural reaction.  A similar phenomenon was
observed in the model study of the LTQ biogenesis, where dopaquinone can be
trapped efficiently by secondary alkyl amines to form LTQ, but not by solvent water
to form TPQ.1 In this model study, primary amines reacted rapidly with the carbonyl
groups of dopaquinone in preference to 1,4-addition.  That such chemistry did not
occur in D298K and is also not seen in LOX strongly suggests that the positioning of
the reactive amine in the active site is key in controlling the chemistry (1,4- vs. 1,2-
addition and hydration vs. amination).
The X-ray crystal structure of D298K (Figure 2.10) suggested a strong
hydrogen bonding interaction (2.4 Å) between O4 of the quinone and the conserved
Tyr284.  This hydrogen bond has been shown to stabilize the quinone as the tautomer,
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lysyl tyrosyl iminoquinone (LTI).  Such an interaction is likely absent in LOX.
Tautomers are proposed as opposed to resonance forms based on the UV/vis data in
which the absorbance spectra of LTQ is red-shifted by ~50 nm from that of LTI. The
double mutant Y284F/D298K was prepared to eliminate the hydrogen bond between
the quinone and Tyr284.  The UV/vis spectrum of Y284F/D298K has a broad
absorbance at 504 nm very similar to the LTQ cofactor (Figure 2.13).1 These results
suggest that the quinone in D298K is stabilized as LTI through a hydrogen bonding
interaction with Tyr284 and such an interaction must be absent for the LTQ cofactor
in LOX.
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Chapter 3: pH Dependency of UV/vis Spectra and Rate of Biogenesis of an LTQ-
like Cofactor in D298K
Introduction
As discussed in chapter 2, the biogenesis of an LTQ-like cofactor occurred
selectively in D298K by the DPQ intermediate reaction with a 1,4-addition of a lysine
side chain, as opposed to the copper bound water molecule as occurs in the natural
reaction. This finding is consistent with results shown for the model study in which
the 1,4-addition of N-methyl-n-butylamine to an in situ generated DPQ at pH 7.2
forms an LTQ-like cofactor exclusively.1 In order to determine if hydration can
compete with amination at lower or higher pHs and to determine how the active site
environments of CAO and LOX contribute to the formation of their corresponding
cofactors, the pH dependency of the rate of biogenesis in D298K was examined.
In HPAO, a study on the pH-dependency of cofactor formation provided
information about the protonation states of the residues in the active site that
participate in the biogenesis reaction. The pH-dependency of the rate of biogenesis in
HPAO showed a sigmoidal curve with a single pKa of 8.45 (Figure 3.1).
69 The pKa
was assigned to the precursor tyrosine of TPQ even though the typical pKa for the
hydroxyl group of tyrosine residue in solution is ~10.  Similarly reduced pKas for
tyrosine residues have been observed in other proteins including glutathione S-
transferase (8.3-8.5), human aldose reductase (8.25), and Fe-containing superoxide
dismutase (8.5).96-98
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In HPAO two UV-vis spectroscopically distinguishable species have been
observed at ~380 nm and ~350 and were proposed to be tyrosine-copper charge
transfer complexes.69,70  The species at ~380 nm in HPAO, grew in over ~3 min and
decayed at about the same rate as the formation of TPQ.70 The ~ 380 nm species
formed and decayed at the same rates when Cu2+ was added to apo enzyme
anaerobically, indicating that its formation was not O2-dependent. Additionally,
mutagenesis of the active site residues immediately flanking the precursor tyrosine
residue, N404D and E406Q respectively, slowed the rate of TPQ formation, but the
rate of formation and decay of the ~380 nm species remained the same, suggesting
that the two are not kinetically coupled. Zn2+ is known to bind tightly to the active site
of apo protein and inhibit the formation of TPQ. The ~380 nm species was observed
when Zn2+ was pre-bound in the active site of the protein and Cu2+ was subsequently
Figure 3.1 Effect of pH on the rate of TPQ biogenesis in WT HPAO. kbio was
determined in buffers varying in pH (!). The data were fit to a function with
differing rates at low and high pH. The value is equal to 12 M-1 s-1 at low pH and
78 M-1 s-1 at high pH, with a pKa of 8.45. Adapted with permission from Schwartz,
B.; Dove, J. E.; Klinman, J. P. Biochemistry 2000, 39, 3699-3707. Copyright
2000 American Chemical Society.
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added, as well as when excess Cu2+ was added to holo-protein.  Taken together, these
results suggest that the formation of the ~380 nm species is not the Cu2+ - precursor
Tyr (Tyr405) charge-transfer complex and that it is likely resulting from a site away
from the active site.
Anaerobic formation and decay of the ~380 nm species in HPAO followed by
aeration of the sample lead to the formation of a new species absorbing at ~350 nm.70
The decay of the ~350 nm species occurs concomitantly with the formation of TPQ.
This species was assigned to a Cu(II) – precursor Tyr (Tyr405) charge-transfer
complex leading to the formation of TPQ. The ~350 nm species grew in to a greater
extent at pH 8.6 than at pH 7.0.69 The increased absorbance could be due to either a
higher extinction coefficient for the deprotonated versus protonated tyrosine or due to
a more favorable pre-equilibrium between the ligated and unligated precursor
tyrosine.
Neither the ~ 380 nm nor the ~ 350 nm species have been observed in the
biogenesis of TPQ in the wild-type AGAO.64 The rate of TPQ biogenesis in AGAO
(1.5 ± 0.2 min-1)65 is ~19-times faster than that in HPAO (0.08 ± 0.03 min-1).69 In
order to characterize the proposed charge-transfer species in AGAO, the UV-vis
spectroscopic studies of the cofactor biogenesis in D298K were conducted, where the
rate of the formation of the LTQ-like quinone (0.05 ± 0.006 min-1) is 30-fold slower




See the Materials section in Chapter 2 for a more comprehensive list of
materials.  HEPBS buffer was purchased from Sigma-Aldrich.  Pyrogallol and ZnSO4
were purchased from Acros.  The biogenesis of WT and D298K was monitored by
UV/vis spectroscopy on an Agilent HP 8453 photo diode array UV/vis
spectrophotometer equipped with a temperature-controlled cell holder at 30 ± 0.2 °C
(path length of 1 cm). The spike in the spectra at 483 nm is an artifact of the
instrument. The biogenesis was also monitored by stopped-flow UV/vis spectroscopy
using a stopped-flow spectophotometer (SX.18MV-R) equipped with a diode array
accessory from Applied Photophysics.
UV/vis spectroscopy
The biogenesis study of WT and D298K was performed as previously
described in chapter 2. Protein samples (25-50 µL) were dialyzed in an Amicon
concentrator five times against 500 µL of the appropriate buffer. Buffers of 100 mM
were used for dialysis.  From pH 6.0 to 6.5, MES buffer was used.  HEPES buffer
was used for pH values from 6.8 to 7.8.  HEPBS buffer was used for pHs 8.0 to 9.0
and CHES buffer was used for pHs 9.2 to 9.5.  CHES buffer was made fresh before
each use.  WT and D298K biogenesis reactions were carried out in air.  The spectra
for the WT samples were taken every 10 sec for 10 min and thereafter, every 1 min
for 20 min in air.  D298K samples were aerobically incubated with 1 mM CuSO4 and
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with 400 mM CuSO4 for comparison with stopped-flow results.  The rates of
formation of the 500-nm and 454-nm chromophores were determined
spectrophotometrically in a reaction mixture containing 0.05 mM apo-D298K and
0.25 mM CuSO4 in 50 mM buffer at the appropriate pH.  The spectra for the D298K
samples were taken every 10 sec for 10 min, every 2 min for 50 min, and every 10
min to 1 hr. The final concentrations of enzyme were determined
spectrophotometrically by using extinction coefficients at 280 nm of 13.2 for 1%
(w/v) solutions of the holo form of AGAO.3
Stopped-flow UV/vis Spectroscopy
WT and D298K samples (150-250 µL) were dialyzed in an Amicon
concentrator five times against 500 µL of the appropriate buffer. Buffer (100 mM)
was used for dialysis.  From pH 6.1 to 6.5, MES buffer was used.  HEPES buffer was
used for pH values from 6.8 to 7.8.  HEPBS buffer was used for pH values from 8.0
to 9.0 and CHES buffer was used for pH values from 9.2 to 9.5.  CHES buffer was
made fresh before each use. The enzyme was diluted to approximately 0.2 mM and
initial concentrations of enzyme were determined spectrophotometrically by using
extinction coefficients at 280 nm of 12.3 for 1% (w/v) solutions of the apo form of
AGAO.3 The instrument was blanked with H2O and rinsed with the appropriate buffer
(injection port A) or 400 mM CuSO4 (injection port B).  Sample was loaded
following the buffer into injection port A.  Sample and CuSO4 were injected
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simultaneously in equal volumes to a final volume of ~100 µL.  Up to 1600 spectra
were taken from 200 to 712 nm over ~20 min.
UV/vis Absorption Spectrum of the Biogenesis Reaction at t = 0
UV/vis spectra were taken of enzyme samples diluted to 0.1 mM (apo sample) at each
pH.  Samples were degassed with argon using a set-up similar to the one used for
oxygenating samples in chapter 2.  Argon was passed through an alkaline pyrogallol
solution prior to purging the cuvette and enzyme solution for 15 min.  A balloon was
filled and degassed; 1 mM CuSO4 or ZnSO4 was added to the cuvette by a gas tight
syringe.  UV/vis spectra were taken immediately, 5 min and 10 min after mixing.
The cuvette was then opened to air to expose the contents to O2 and allow biogenesis
to take place.  After at least 30 min, the concentration of the sample was determined
spectrophotometrically by using the extinction coefficient at 280 nm of 13.2 for 1%
(w/v) solutions of the holo form of AGAO.3
UV/vis Spectral Change Following the Addition of Metal to Holo-AGAO
Holo-WT and holo-D298K were prepared by incubation with an excess (four
molar equivalents) of Cu2+ and the corresponding apo-proteins at pH 6.8 in 100 mM
HEPES or pH 8.5 in 100 mM HEPBS.  The holo samples were dialyzed in the same
buffer in an Amicon concentrator to remove excess Cu2+.  The protein concentration
was adjusted to ~ 0.2 mM and UV/vis spectra were recorded.  An equal volume of 1
mM CuSO4 was then added to each sample and UV/vis spectra were taken
immediately, 5 min and 10 min after mixing.  The concentrations of the samples were
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determined spectrophotometrically by using extinction coefficients at 280 nm of 13.2
for 1% (w/v) solutions of the holo form of AGAO.3 Zn2+-containing WT and D298K
samples at pH 6.8 and 8.5 were dialyzed to remove excess Zn2+.  The protein
concentration was adjusted to ~ 0.2 mM.  A spectrum was taken and an equal volume
of 1mM CuSO4 was added to the sample.  Spectra were taken immediately, 5 min and
10 min after mixing.  The concentrations of the samples were determined
spectrophotometrically by using extinction coefficients at 280 nm of 13.2 for 1%
(w/v) solutions of the holo form of AGAO.3  Apo-WT and apo-D298K samples were
incubated aerobically with 1 mM ZnSO4 pH 6.8 and 8.5 for 1 hour.  The sample was
dialyzed to remove excess Zn2+ and a spectrum was taken.  Samples were further
dialyzed in the presence of 10 mM EDTA and the appropriate buffer.  Dialysis to
remove excess EDTA was done prior to taking a spectrum of each sample.  The
concentration of the sample was adjusted to 0.1 mM and an equal volume of 1 mM
CuSO4 was added to each sample.  Spectra were taken immediately, 5 min and 10
min after mixing.  The concentration of the samples were determined
spectrophotometrically by using extinction coefficients at 280 nm of 12.3 for 1%
(w/v) solutions of the apo form of AGAO.3
Data Analysis
The UV/vis spectra were baseline corrected at 800 nm and normalized to a
concentration of 0.1 mM enzyme.  The observed rate constants (kobs) for formation
and decay of 500 nm chromophore and formation of the 454 nm chromophore were
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determined by fitting absorbance changes at 320 nm, 454 nm and 550 nm plotted
versus time by least square fitting to the sum of two single exponentials (Equation
3.1) using Kaleidagraph (Synergy software).  The plot of rate versus pH for the first
phase was fit to equation 3.2 and the plot for the second phase was fit to equations 3.2
(sigmoidal curve) and 3.3 using (bell shaped curve) Kaleidagraph (Synergy software).
Average values of at least two independent measurements are taken.
! 
rate = Abs1 *10
("k1 *t ) + Abs2 *10
("k2 *t ) + Abs3 (3.1)
! 
rate = kmax /(1+10
(pKa "pH)) (3.2)
! 




pH-Dependence of the UV-vis Spectra of the LTQ-like Quinone and LTI Biogenesis in
D298K
In order to determine the effect of pH on the biogenesis of the LTQ-like
cofactor in D298K, the time-course of biogenesis was followed by UV/vis
spectroscopy at various pHs from 6.8 to 9.5 under aerobic conditions. Buffer outside
this pH range could not be used due to protein precipitation/denaturation. Over the pH
range studied, similar spectroscopic changes were observed as those of the biogenesis
at pH 6.8, described in chapter 2, in which the peak at ~500 nm, proposed to be an
LTQ-like quinone, forms quickly followed by its slow decay and an increase of
absorbencies at ~450 nm and ~320 nm from LTI.  Although the overall spectral
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changes are consistent, there is a shift in the &max of the ~500 nm species across the
pH range.  At pH 6.8, the &max is ~496 nm (Figure 2.16 a), which shifts to ~502 nm
from pH 7.5 to 8.7 (Figure 3.2 a) but shifts to ~518 nm at pH 9.5 (Figure 3.3 a). This


























































































Figure 3.2 D298K biogenesis at pH 8.4.  UV/vis spectral changes after the
addition of Cu2+ to apo-D298K in air at pH 8.4 (final concentrations: 50 mM
HEPBS, 50 µM D298K, 250 µM CuSO4).  Data were normalized to 0.1 mM
D298K and the spectra of apo D298K at the corresponding pH was subtracted  a)
First phase: absorption spectra were recorded at 0.5, 1, 1.5, 2, …10 min. b)
Second phase: absorption spectra were recorded at 10, 20, 30,…120 min. c)
Absorbance changes at 320 (!), 454 (#), 550 nm (!) were plotted against time




first phase. The neutral form of the LTQ model compound in solution that is fully
solvated, shows a &max of 504 nm and when the butylamino side chain is deprotonated,
the &max shifts to 450 nm where the pKa was determined to be 10.33 ± 0.07.
1 The




















































































Figure 3.3 D298K biogenesis at pH 9.5.  UV/vis spectral changes after the
addition of Cu2+ to apo-D298K in air at pH 9.5 (final concentrations: 50 mM
CHES, 50 µM D298K, 250 µM CuSO4).  Data were normalized to 0.1 mM
D298K and the spectra of apo D298K at the corresponding pH was subtracted  a)
First phase: absorption spectra were recorded at 0.5, 1, 1.5, 2,…10 min. b) Second
phase: absorption spectra were recorded at 10, 20, 30,…120 min. c) Absorbance
changes at 320 (!), 454 (#), 550 nm (!) were plotted against time and fitted to





1 The origin of the 20 nm red-shift observed for the LTQ-like quinone in D298K
at pH 9.5 is not clear. At all pHs the conversion of the ~500 nm species to the ~450
nm species occurs with an isosbestic point at ~465 nm, and the peak ~450 nm does
not appear to be shifted at any pH under the reaction conditions (Figures 3.2 and 3.3
panel b).  It should be noted that, within the pH range studied, the formation of TPQ
was not observed as in the case of the model study.1 This result suggests that, in
general, the amination of the DPQ intermediate is more efficient than hydration.
pH-Dependence on Rate for the Biogenesis of an LTQ-like Cofactor in D298K
The pH-rate profile for the biogenesis of the LTQ-like species should provide
information about the protonation states of titratable active site residues that are
involved in the cofactor biogenesis.  The effect of pH on the rate of biogenesis of the
first phase yielded a bell shaped curve with optimal pH of ~8.8 with the maximum
Figure 3.4 Effect of pH on the rate of biogenesis of the 505 nm (a) and 450 nm
(b) species in D298K were determined in buffers of varying pH.  Rates were
determined from plots of "absorbance at 550 nm or 443 nm, respectively, vs.
time, like those seen in Figures 3.3 and 3.4 panels c. The data were fit to least-



















































rate of 0.77 ± 0.063 min-1 under aerobic conditions (Figure 3.4 a).  pKa
1 of 7.93 ± 0.10
and pKa
2 of 9.62 ± 0.13 were determined by the least-square fit analysis of data using
equation 3.2. Similarly, the pH-profile of the second phase of biogenesis was also fit
to equation 3.2, resulting in a bell shaped curve that was slightly broader than that of
the first phase (Figure 3.4 b).  The optimal pH for the second phase is ~8.9 with a
maximum rate of 0.037 ± 0.002 min-1, pKas of 7.68 ± 0.086 and 10.23 ± 0.22, and an
R2 value of 0.945 were determined by the least-square curve fit analysis using
equation 3.2. Alternatively, the pH-profile of the second phase was fit to equation 3.3
resulting in a sigmoidal curve (Figure 3.4 b). The optimal pH for the second phase
with this fitting is above ~9.5 with a maximum rate of 0.034 ± 0.001 min-1, a pKa of
7.55 ± 0.093, and an R2 value of 0.897. Although the curve fitting of equation 3.2 fits
better to the data for the second phase, it is possible that the rate of the second phase
plateaus and the slight decrease in observed rate is due to partial denaturation of the
protein. Therefore, it is not possible to determine the accuracy of the pKa of 10.23 due
to the denaturation of the protein above pH 9.5.
The pKa of 7.93, observed in the first phase of D298K biogenesis, is 0.5 pH
unit-lower than the value reported for the wild-type of HPAO; it is most likely that
the pKa corresponds to the precursor tyrosine as well. The later pKa of 9.62 has not
been seen previously in CAOs. The active site of D298K lacks Lys or Arg residues,
with pKas of ~11-13, other than K298. However, the active site does contain several
Tyr residues. Deprotonation of the residue responsible for the pKa of 9.62 results in a
slower rate of biogenesis of the LTQ-like cofactor in D298K.  If the amino group of
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K298 were being titrated and the rate of the reaction between deprotonated K298, and
DPQ became rate limiting, a spectral feature for DPQ (&max ~ 380 nm)
99,100 should be
apparent in the UV/vis spectra. Additionally, slowing the reaction between DPQ and
K298 could allow for a competition between hydration and amination. However, at
higher pHs, spectral features were not observed for the DPQ intermediate or TPQ;
therefore, it is unlikely that K298 was being titrated. It is more likely that the pKa was
the result of an active site Tyr residue.
Examination of the active site of the D298K crystal structure shows four Tyr
residues near the LTQ-like cofactor (Figure 3.5 a). However, upon closer inspection,
it is apparent that the OH groups of two of the residues, Tyr296 and Tyr302, are
pointing away from the cofactor and, most likely, are not involved in the biogenesis
reaction (Figure 3.5 b).
Tyr296 and Tyr302 are both outside the wedge-shaped cavity in the active site
of CAO.7 The wedge-shaped cavity is formed by Val282 and Asn381 positioned on
either side of TPQ.  Additionally, Tyr284 appears to serve a role as a gate keeper,
holding TPQ in the wedge so that it does not move out of the wedge and get trapped
by Cu2+. Mutation of the residue corresponding to Tyr284 in ECAO resulted in the
TPQ being flipped and swung out of the wedge, decreasing the rate of catalysis ~ 50
fold.101 D298 is positioned on the opposite side of TPQ from Tyr284. Mutation of this
residue to Ala in ECAO resulted in the increased mobility of TPQ, thus decreasing






















Figure 3.5 Active site structure of D298K a) in the perpendicular view of the LTI
cofactor and b) in the nearly parallel view of the LTI cofactor.  Residues
potentially responsible for the pKa seen at 9.62 and 10.23 are shown in blue.
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TPQ15 while in HPAO the corresponding mutation led to an increase in mobility.54
However, both mutations lead to a decrease in the rate of catalysis suggesting that
TPQ requires some mobility but that movements of TPQ are tightly controlled for
optimal activity. Tyr296 is located at the base of the proposed substrate entry channel
but is not part of the active site cavity. 7Similarly, Tyr302 is near the bottom of the
proposed substrate entry channel and may have a role in hydrogen bonding or *-
stacking but is not part of the active site cavity.44,102
Tyr384 is also near the wedge-shaped cavity; it is ~3.7 Å from the !-amino
group of Lys298. Mutation of the corresponding residue, Tyr404, to Phe in histamine
oxidase from A. globiformis had no effect on cofactor biogenesis.78 It did, however,
decrease the rate of catalysis and altered the substrate specificity indicating that this
residue plays a role in substrate binding. Deprotonation of this residue in D298K may
lead to a salt bridge with the protonated !-amino group of the lysine residue prior to
cross-linking. This may hold Lys298 in a position where it is unable to react with
DPQ. If this were the case, a spectral feature for DPQ should be observed ~ 380 nm,
as discussed previously,99,100 but this is not observed experimentally. Therefore, it is
unlikely that this residue is being titrated in the pH-profile.
It is possible, during the first phase of biogenesis of the LTQ-like cofactor,
that a hydrogen bonding interaction exists between Tyr284 and the C4 carbonyl group
of DPQ to position the quinone and allow the 1,4-addition to occur. As discussed in
chapter 2, DPQ can be trapped by Lys298 so it must have mobility in the active site
that is similar to the mobility of TPQ and it must be able to come off Cu2+. If Y284 is
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hydrogen bonding with DPQ, Tyr284 could be responsible for the pKa of 9.62 seen in
the first phase of biogenesis. Deprotonation of Y284 would inhibit hydrogen bonding
and could result in DPQ swinging out of the wedge and onto Cu2+.
In the second phase of D298K biogenesis, LTQ is thought to be converting to
the more thermodynamically favored LTI. Tyr284, most likely, facilitates the
conversion. As discussed in chapter 2, the mutation of Tyr284 to a Phe, in D298K,
results in an unstable species with &max ~505 nm, and conversion to the ~450 nm
species does not occur. If the pKa were from the amino group of LTQ, it would be
lower in the enzyme  (~ 7.55 - 7.68) than in the model system (10.33) and LTQ would
be deprotonated at pH 8.8. The LTQ/LTI monoanion would have an absorbance of
~450 nm as seen in chapter 2 for the model compounds. However, the rate of
conversion of the ~505 nm species to the ~450 nm species, although slightly faster,
remains very slow, where at pH 8.8 the 450 nm species should form very fast, making
this possibility very unlikely. Therefore, it is likely that the pKa of 7.55 - 7.68 results
from a tyrosine residue, most likely Tyr284.
In the resting state, TPQ exists as a resonance stabilized mono-anion where
resonance occurs between the C2 and C4 carbonyls and deuterium exchange of the
C3 proton has been observed.26,49,50,66,103 However, LTQ exists as a neutral ortho-
quinone where deuterium exchange at C3 was not observed.1,91 If Tyr284 is being
titrated in the pH profile of the second phase, deprotonation of Tyr284 would be
catalyzing the rate of thermodynamic equilibrium between LTQ and LTI (Scheme
3.1).  When Tyr284 is deprotonated, LTI can still hydrogen bond with Y284,
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stabilizing it over LTQ.  The extent of hydrogen bonding between residues is known
to directly effect the pKa of the residues. Therefore, it is possible for Tyr284 to have a
pKa of 9.65 in the first phase and ~7.5 in the second phase. In CAOs, the active site
base, a conserved aspartate residue with a typical pKa of ~ 4, has a pKa of 7.5 in
AGAO that shifts to 6.5 in the enzyme substrate complex,46 8.1 in HPAO,55 8.0 in
BSAO that shifts to 5.6,40,104 and 6.2 in ECAO.15 The increased pKas of the active site
bases in CAOs have been attributed to a charge repulsion between the C4 oxoanion of
































TPQ and the active site base35,55 as well as the hydrophobic environment of the active
site.55 The pKa of a phenol in water is ~10
105 but it is ~18 in DMSO.106 The OH group
is more ionizable when it is able to participate in hydrogen bonding interactions. It is
likely that the hydrogen bonding interaction between Tyr284 and DPQ in the first
phase is weaker than the hydrogen bond between Tyr284 and LTQ/LTI in the second
phase.
 pH-Dependence of the UV/vis Absorbance Spectra of the Charge Transfer Complex
Formed During the Biogenesis of an LTQ-like Cofactor in D298K
During the initial seconds of cofactor biogenesis in D298K, a peak at ~370 nm
was observed which had not been observed in WT biogenesis in AGAO.64 The
species can, however, be seen during the biogenesis of the TPQ cofactor in WT
AGAO when monitored by stopped-flow spectroscopy (Figure 3.6) but the species is
no longer visible after ~ 3 sec. In WT HPAO, however, two similar species have been
observed at ~380 nm and ~350 nm both of which are proposed to be tyrosine-copper
charge transfer species.69,70 The species resulting in the absorbance ~380 nm was
determined to be independent of O2 while the species with an absorbance of ~350 nm
was O2-dependent. In order to determine if the ~370 nm species observed in D298K
was O2-dependent, the time course of the reaction was monitored by UV/vis
spectroscopy under anaerobic conditions.
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The ~ 370 nm species appeared to be fully formed in the mixing time of the
reaction (30 sec) and the species decayed over the next several minutes (Figure 3.7),
indicating that the formation of the species is not O2-dependent. However, the rate of
decay of the species appears to be faster under aerobic conditions (less that one
minute) than under anaerobic conditions (5 – 10 minutes). Moreover, the rates of
cofactor biogenesis do not seem to coincide with the rate of ~370 nm species decay,
and an isosbestic point was not observed, indicating that the species does not convert
directly to the fully formed cofactor. In HPAO, the species leading to the formation of
TPQ was proposed to be an O2 dependent Cu
1+ - tyrosyl radical (Scheme 3.2 species
C); however, this species has not been observed by EPR.69 If the same mechanism is
occurring in WT- and D298K-AGAO, it is possible that the ~ 370 nm species is
Figure 3.6 Biogenesis of 0.1 mM WT with 0.5 mM CuSO4 in HEPES at pH 7.2
monitored by stopped-flow UV/vis spectroscopy. —0.1638 sec, —3.441 sec,
—6.717 sec, —9.994 sec, —23.1 sec, —32.93 sec, —42.76 sec, —52.59 sec,
—62.42 sec, —121.4 sec, —180.4 sec, —242.4 sec, —301.6 sec, —360.6 sec,




















forming off pathway and prior to the reaction with O2 as shown in Scheme 3.2 A to
Y.
It is possible that in AGAO, species C could form anaerobically, leading to
the absorbance of ~ 370 nm (Scheme 3.3). The species would exist in equilibrium
with Tyr + Cu2+ (A) and the Cu2+ - tyrosinate complex (B) and, under anaerobic






















Figure 3.7 UV/vis spectra of the 370 nm species seen in the reaction of apo
D298K with Cu2+ under anaerobic conditions at pH 8.5  —apo, —30 sec, —5
min, —10 min. Samples were blanked with buffer (apo) or a mixture of buffer
and copper.
Scheme 3.2 Proposed mechanism of charge-transfer complex formation in
HPAO.






shifting to the thermodynamically favored species.  If this were the case, under
aerobic conditions the conversion of species C to TPQ should occur concomitantly
and an isosbestic point would be observed. Neither were observed, indicating that
species C is not the ~ 370 nm species.
The 370 nm species could be forming off pathway where the ~370 nm species
(Scheme 3.3 species X) is in equilibrium with A or B, or it could be forming in a site
other that the active site. In order to determine if this charge transfer complex is
forming between the precursor tyrosine and Cu2+ (i.e. in the active site), the apo WT
and D298K proteins were reacted with Zn2+, which binds tightly in the active site of
the protein but inhibits the formation of the cofactor. Upon the addition of Cu2+ to the
Zn2+ substituted protein (dialyzed in EDTA to remove excess Zn2+), the peak ~370 nm
was not observed, indicating that the ~370 nm species is resulting from a charge
transfer complex forming between the precursor tyrosine in the active site and Cu2+,
as opposed to forming outside of the active site like the ~ 380 nm species observed
Scheme 3.3 Possible mechanism of ~ 370 nm species formation.





for HPAO. The addition of excess Cu2+ to holo-proteins resulted in a peak at ~ 320
nm in WT and ~350 nm in D298K at pH 8.5 that was not observed at pH 6.8 (Figure
3.8). The peaks are not fully formed at 30 sec and do not decay in the time course of
the experiment. Additionally, the ~ 320 nm species in WT accumulates to a much
greater extent than ~ 350 nm species in D298K or in either apo protein. It is likely
Figure 3.8 UV/vis difference spectra of holo WT (panels a and b) or D298K
(panels c and d) upon the addition of copper at —30 sec, —5 min and —10 min
minus holo WT or D298K without excess copper at pH 6.8 (panels a and c) and








































































that these new absorbencies are not resulting from the same potential charge transfer
species seen at ~370 nm but a species that is forming outside of the active site.  The
370 nm species, however, is likely a charge transfer species formed in the active site
of WT- and D298K-AGAO but not on the pathway to form the cofactor.
A pH-dependency of the UV-vis spectrum of the species was also observed
under anaerobic conditions, in which the UV/vis spectra taken 30 sec after the
addition of Cu2+ to D298K produced a more defined peak at pHs from 7.8 to 9.0
where the rate of cofactor formation was the fastest (Figure 3.9). However, pH did
not appear to consistently effect the extent of accumulation of the ~370 nm peak as
was seen in HPAO.69 The anaerobic spectra of WT protein taken at pH 6.8 and 8.5
also resulted in the rapid formation of the ~370 nm species, but the peaks were not





















Figure 3.9 UV/vis spectra of the 370 nm species seen in the reaction of apo
D298K with Cu2+ under anaerobic conditions at 30 sec and pHs of —6.8, —7.8,




The time course of the UV-vis spectral change observed during the biogenesis
reaction in D298K varied based on the pH at which the reaction took place. At pH 6.8
the absorbance of the initially formed species was ~496 nm.  A shift to 505 nm
occurred with a change in pH from 7.5 to 8.7.  At a pH of ~9.5, the species shifted to
~518 nm. This shift in &max, likely corresponds to the amount of LTI present at the end
of the first phase. The conversion of this species to the 450 nm species occurred with
an isosbestic point at ~465 nm and produced a peak at ~ 450 nm at each pH. The
formation of TPQ was not observed at any pH indicating that amination out competes
hydration at the pH range studied.
The pH-profile of D298K biogenesis, followed by UV/vis spectoscopy,
indicated that the rate of biogenesis of the 505 and 450 nm species are both pH-
dependent. The pH-dependency on the rate of formation of the LTQ-like species in
the first phase produces a bell-shaped curve with pKas of ~7.93 and 9.62. The rate for
the formation of this species was the fastest at a pH of ~ 8.8 with a rate of 0.77 min-1.
Deprotonation of the residue in the active site with a pKa
 of ~ 7.9, increases the rate of
the reaction and the residue is proposed to be the precursor tyrosine, as was seen
previously in HPAO with a pKa of ~8.45.
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Protonation of the residue with a pKa of 9.62 in the first phase, increases the
rate of the reaction; this pKa has not been observed previously in CAOs. This pKa was
proposed to be Tyr284, where it most likely is involved in a hydrogen bonding
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interaction with DPQ, holding DPQ in the wedge shaped cavity to react with Lys298
and keeping it from being trapped by Cu2+.
In the second phase of biogenesis, Tyr284 is known to hydrogen bond to
LTQ/LTI to stabilize the LTI tautomer over LTQ. When Tyr284 was mutated to Phe
in D298K, the ~ 505 nm peak for LTQ was observed but did not convert to the ~ 450
nm LTI peak (as seen in chapter 2). In the second phase, the deprotonated form of
Tyr284 was proposed to increase the rate of LTQ to LTI conversion although the
conversion is thought to be thermodynamically dependent. Deprotonation of Tyr284
may be influencing the thermodynamic equilibrium.
The differences in the pKas of Try284 in the first and second phase is most
likely due to the different environments of Tyr284 in the two phases. In the first
phase, Tyr284 is probably only weakly hydrogen bonded to DPQ. In chapter 2, DPQ
was shown to have mobility in the active site. It would have to move out of the active
site wedge and interact with Cu2+ to undergo a hydration reaction to form TPQ in
WT. Therefore, the hydrogen bond between Tyr284 and DPQ should be fairly weak.
However, the hydrogen bonding interaction formed between LTQ/LTI and Tyr284 is
likely stronger, as indicated by the lower pKa.
In the initial minute of cofactor biogenesis in WT- and D298K-AGAO, an
absorbance at ~370 nm, proposed to be a charge-transfer species, was observed. The
formation of the species was not O2-dependent as it forms under both aerobic and
anaerobic conditions. The putative charge transfer species may be formed off
pathway, as suggested by the different rates of cofactor formation and ~ 370 nm
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species decay and by the lack of an isosbestic point between the 370 nm and 505 nm
species. However, it is probably formed in the active site of the protein because it was
not observed when Zn2+ was prebound in the active site or when Cu2+ was added to
holo protein. A different putative charge transfer species was observed when Cu2+
was added to holo protein, which likely originates from outside of the active site.
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Chapter 4: LTQ Biogenesis in WT- and D298A-AGAO in the Presence of n-
Butylamine
Introduction
Copper amine oxidase, containing TPQ, catalyzes the oxidative deamination
of amine substrates to their corresponding aldehydes.  As discussed in chapter 1, the
reaction is divided into reductive- and oxidative-half reactions.  In the reductive half
reaction, the C5 carbonyl group of TPQ reacts with substrate to form a substrate
Schiff base.  A conserved aspartic acid residue (Asp298 in AGAO) then acts as a
general base to abstract the ) proton of the substrate, leading to the product Schiff
base.35 Mutation of Asp298 to Ala reduced the catalytic efficiency about 106 fold
compared to that of WT.46 Similarly, when D298A was reacted with phenylhydrazine,
the rate of the reaction was slowed ~170 fold.46 In the biogenesis reaction of TPQ in
D298A-AGAO, the rate of the reaction was 40% slower than that of WT.46 However,
the TPQ content was approximately that of WT, indicating that Asp298 is not directly
involved in the biogenesis of TPQ.
In chapter 2, Asp298 was mutated to a Lys residue and was shown to form an
LTQ-like cofactor during biogenesis, which was stabilized in the form of the LTI
tautomer.  The cofactor was formed through the cross-linking of two amino acid
residues, making it immobile and unable to rotate freely like the TPQ cofactor. In the
flipped orientation, the C5 active carbonyl is away from the substrate entry channel
and Asp298, making it inactive.  In an attempt to trap the DPQ cofactor with a free
amine and to generate an LTQ-like cofactor in AGAO (Scheme 4.1) with an
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increased mobility, WT- and D298A-AGAO were biogenized in the presence of n-
butylamine. In chapter 2, the proper placement of the Lys residue in the active site
was required for the formation of LTQ.  In that study, the Asp298 residue was
mutated to a Lys to form LTQ.  Therefore, the mutation of Asp298 to Ala should
create room in the active site to accommodate the n-butylamine at a position to allow
a cross-link to form.
Materials and Methods
Materials
See the Materials section in Chapters 2 and 3 for a more comprehensive list of
materials. Potassium sodium tartrate, magnesium acetate, methylamine
hydrochloride, and sodium periodate were purchased from Sigma Aldrich. Dioxane,
CAPS, butylamine, and potassium carbonate were purchased from Acros.  Sodium
cacodylate and PEG 8000 were purchased from Fluka. The 50 µL microdialysis
buttons and microdialysis membrane disks of 12,000-14,000 MW cut off were































The expression plasmid for D298A-AGAO was generated by site-directed
mutagenesis using a QuikChange mutagenesis kit from Stratagene using pPEAO-0235
as the parent vector.  The DNA primers for D298A were 5( -
A G A A C T A C T T C G C T A C G G G G G A G T A C C T G - 3 ( (forward) and 5(-
CAGGTACTCCCCCGTAGCGAAGTAGTTCT-3( (reverse).  The plasmid was fully
sequenced and the point mutation was confirmed.  The plasmid was propagated in E.
coli DH5) cells and purified using high-speed plasmid mini- and midi-prep kits from
Qiagen.
Enzyme Expression and Purification.
The precursor forms of WT and D298A were optimally expressed using the
procedure described in chapter 2 for the precursor form of WT and D298K proteins.
Protein concentrations were determined spectrophotometrically by using extinction
coefficients at 280 nm of 12.3 for 1% (w/v) solutions of the apo form of AGAO.29
Protein not being used immediately was stored at -80°C in 40 mg/mL aliquots with
the addition of 25% glycerol as a cryoprotectant.
Biogenesis Study
To determine if an LTQ-like quinone could be made by cross-linking of DPQ
to a free amine, the biogenesis of apo WT and D298A was done in the presence and
absence of n-butylamine hydrochloride at 30°C.  A 50 µL solution of 0.2 mM enzyme
95
in 100 mM HEPES pH 6.8, 100 mM CAPS pH 10, 100 mM CHES pH 9, or 100 mM
HEPBS pH 8.5 was mixed with 50 µL 1 mM CuSO4. Methylamine hydrochloride or
n-butylamine hydrochloride (25 µL of 4 mM or 400 mM in 500 mM buffer) was
added to 25 µL of 0.4 mM enzyme.  The solution was incubated at room temperature
a few minutes before adding 50 !L of 1 mM CuSO4.  The progress of the reaction
was monitored by UV/vis spectroscopy.  Spectra were taken every 10 sec for 10 min
and every 2 min for 50 min. UV/vis spectroscopy was performed on an Agilent HP
8453 photo diode array UV/vis spectrophotometer equipped with a temperature-
controlled cell holder at 30 ± 0.2 °C (path length of 1 cm).
WT and D298A samples were biogenized in the presence of amine
hydrochloride salts, as described above, for 30 min at pH 8.5, 9, and 10.  Spectra were
taken before spin dialysis 5x into 100 mM HEPES pH 6.8.  The samples were diluted
to 0.1 mM and spectra were taken again. The final concentrations of enzyme were
determined by using extinction coefficients at 280 nm of 13.2 for 1% (w/v) solutions
of the holo form of WT-AGAO.29
Reaction with 2-Hydrazinopyridine or Methylhydrazine
Enzyme solutions of 100 µL of 28.2 mg/mL D298A with n-butylamine
hydrochloride were prepared in 200 mM KPi pH 7.2.  Five molar equivalents of 2-
phenylhydrazine were added (25 µL of 0.1 mM) and the solution was incubated at




The purified D298A apo-protein (0.4 mM) was incubated at room temperature
for 5 min with 377 mM n-butylamine hydrochloride in 471 mM CAPS pH 10.  An
equal volume of 0.5 mM Cu2+ was added, and the reaction was incubated at 30°C for
one hour to complete the cofactor biogenesis.  The product was dialyzed against 1 L
50 mM HEPES pH 6.8 twice (1 hour and overnight).  Samples were diluted to 5, 10,
and 15 mg/mL, and crystal trays were set up using both the hanging drop vapor
diffusion and button dialysis methods.  The hanging drop method used 1-2 µL
enzyme and an equal volume of crystallization buffer.  The well contained 750 µL
crystallization buffer.  The button method was carried out in 50 µL buttons; ~27 µL
enzyme and crystallization buffer were added to the button.  The well contained 1.5
mL crystallization buffer.  All crystal trays were incubated at 20°C.  Four
crystallization buffers were used based on previous CAO crystallization experiments:
1) 200 mM magnesium acetate, 20% (m/v) PEG 8000, 100 mM sodium cacodylate
pH 6.5107  2) 1.6 M ammonium sulfate, 10% (v/v) dioxane, 100 mM MES pH 6.5107
3) 1.6 M ammonium sulfate, 12% (v/v) dioxane, 100 mM MES pH 6.5107  4) 1.05 M
potassium sodium tartrate, 25 mM HEPES pH 6.8.12
Results
Expression and Purification of Wild-type and Mutant AGAOs
Protein expression yielded approximately 105 - 110 g of wet E. coli cells. The
D298A mutant behaved the same as WT during expression and purification.  Table
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4.1 shows a summary of the yields. The purity of the samples were ~99% as
estimated from the SDS-PAGE gels.
Biogenesis of LTQ-like Quinone in WT and D298A
The time course of cofactor formation in the presence and absence of n-
butylamine hydrochloride was followed by UV/vis spectroscopy in WT- (Figure 4.1)
and D298A-AGAO (Figure 4.2) protein samples. The apo-D298A was prepared by
the standard procedure used to prepare apo-WT.12,29 The apo-WT or D298A proteins
were mixed with a solution of n-butylamine in buffer, briefly incubated, and further
mixed with a Cu2+ solution in air at 30°C (final concentrations of 0.1 mM enzyme,
0.1 M n-butylamine hydrochloride, 0.15 M buffer, and 0.5 mM CuSO4 or 0.1 mM
enzyme, 50 mM buffer, and 0.2-0.5 mM CuSO4).  The biogenesis reactions of WT
and D298A in the absence of n-butylamine at pH 6.8 are known to produce a TPQ
cofactor with absorbencies of ~475 nm35 and ~460 nm46 respectively with no
observed intermediates, as was seen in this study. However, the biogenesis of WT and
D298A in the presence of n-butylamine produced a pink species with a broad visible
absorbance centered at ~538 nm in WT and ~523 nm in D298A at pH 8.5. Cofactor
biogenesis of D298A in the presence of methylamine was also monitored but resulted
Table 4.1 Protein yields for apo protein with optimized growth and purification
conditions




in absorbance spectra with a peak ~460 nm that was concluded to be TPQ. It is likely
that the active site is not arranged to facilitate the reaction with methylamine. In the
D298A n-butylamine sample, the peak, centered at 523 nm, shifted to ~500 nm as the
reaction progressed from 10 min to 1 hr.  The peak ~500 nm is very similar to that of
Figure 4.1 Biogenesis of WT in the presence and absence of n-butylamine. a)
Biogenesis of 0.1 mM WT with 0.2 mM CuSO4 in HEPBS at pH 8.5.  b)
Biogenesis of WT in the presence of 0.1 M n-butylamine hydrochloride with 0.5
mM CuSO4 in HEPBS at pH 8.5. c) and d) are the difference spectra of a and b,
respectively, minus the spectra taken in the absence of CuSO4. —1 min, —2
min, —3 min, —4 min, —5 min, —7 min, —9 min, —11 min, —13 min,








































































Table 4.1 Protein yields for 
conditions
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the LTQ model compound (Figure 2.9). The biogenesis of WT in the presence of n-
butylamine was initially being studied as a control, but it appears that the same
species is being formed in both WT and D298A.  If this species is an LTQ-like
quinone, the results support those found in the study of D298K in chapter 2, showing
















































































Figure 4.2 Biogenesis of D298A in the presence and absence of n-butylamine. a)
Biogenesis of 0.1 mM D298A with 0.5 mM CuSO4 in HEPBS at pH 8.5.  b)
Biogenesis of D298A in the presence of 0.1 M n-butylamine hydrochloride with
0.5 mM CuSO4 in HEPBS at pH 8.5. .c) and d) are the difference spectra of a and
b, respectively, minus the spectra taken in the absence of CuSO4. —1 min, —2
min, —3 min, —4 min, —5 min, —7 min, —9 min, —11 min, —21 min,
—31 min, —41 min, and —51 min
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natural hydration reaction to form TPQ. However, this study indicates that the free
amine, and not just the bound Lys, is capable of undergoing the 1,4-addition reaction
(Scheme 4.1). These results are also in agreement with the results observed in model
studies of LTQ biogenesis, where DPQ can be trapped by secondary alkyl amines to
form LTQ, but not by solvent water molecules to form TPQ.1 Crystallographic studies
may help to determine how the active sites in WT and D298A are arranged to
accommodate n-butylamine, facilitate its reaction with DPQ, and lead to products
with differing energies.
Absorbance changes at the initial &max for each species are plotted against time
in Figure 4.3. The preliminary rates of biogenesis for WT and D298A with and
without n-butylamine at pH 8.5 were each fitted to the sum of two single exponentials
by the least-square method (Table 4.2).  Compared to the rate of WT biogenesis,







































Figure 4.3 Preliminary rates of biogenesis for a) WT and b) D298A % with and
% without n-butylamine at pH 8.5 fit to the sum of two exponentials by the least-
square method
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amine was ~2.3 x slower.  The faster rate of biogenesis of D298A in the presence of
amine compared to the biogenesis in the absence of amine supports the observation
that the 1,4-addition of the amine to DPQ is more efficient than the addition of a
copper associated water molecule. However, the rate of WT biogenesis in the
presence of amine was ~9 x slower than the rate in the absence of amine, possibly
indicating that the active site of the WT enzyme is not arranged to accommodate the
amine in an appropriate place to react efficiently with DPQ.
 In addition to the biogenesis reactions of D298A at pH 8.5, biogenesis




































Figure 4.4 Final D298A biogenesis spectra at pH %8.5, %9.0 and %10.0 minus
the initial apo spectra. a) Biogenesis in the absence of BuNH3
+. b) Biogenesis in
the presence of BuNH3
+.
Table 4.2 Preliminary rates of cofactor biogenesis in the presence and absence of
n-butylamine in WT- and D298A-AGAO
Sample !max Rate (min
-1)
WT 475 2.66
WT with n-butylamine 538 0.295
D298A 458 0.613
D298A with n-butylamine 523 1.17
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hr of D298A biogenesis with and without n-butylamine, minus the initial (apo)
spectra at pH 8.5, 9.0 and 10.0.  In the absence of n-butylamine, the final absorbance
of cofactor formation in D298A shifts from ~460 nm at pH 8.5 to ~480 nm at pH 9.0
and 10.0.  Similarly, the biogenesis reactions of D298A in the presence of n-
butylamine resulted in peaks ~500 nm at pH 8.5 and 515 nm at pH 9.0 and 10.0. It is
possible that at the higher pHs, the hydrogen bonding interaction between O4 of the
quinone and Tyr284 is weaker and allows for a greater extent of electron density
delocalization, leading to the red-shift observed in the absorbance spectra. In D298A,
the crystal structure at 1.85 Å resolution shows that O4 of TPQ is 2.3 Å from Tyr284
as opposed to the 2.5 Å seen in WT at 1.8 Å resolution.12,46 The ~30 nm blue-shift in
the absorbance spectra of D298A to ~460 nm, has been attributed to this stronger
hydrogen bonding interaction causing a localization of electron density at the O4
position of TPQ.46 Additionally, in the D298A crystal structure, Y296 is rotated into
the space created by the D298A mutation and a water molecule occupies the space
created by the rotation of Tyr296.  The water molecule is also hydrogen bonded to the
O4 of TPQ and is likely contributing to the localization of electron density at that
location.46 The absorbance spectra of D298K also shows a ~30 nm blue-shift
compared to WT.4 In the crystal structure of D298K-AGAO, the location of Tyr296 is
similar to its position in WT and an additional water molecule is not seen near O4 of
LTI.  The hydrogen bonding distance between LTI and Y284 is ~2.4 Å.  However,
disruption of the hydrogen bond between O4 of the quinone and Tyr284 by site-
directed mutagenesis results in an absorbance spectram that is red-shifted ~50 nm,
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supporting the observation that the localization or delocalization of electron density at
O4 leads to differences in the electronic features of the quinone.4
In order to determine if the 500-515 nm absorbance is from a TPQ cofactor
that was shifted due to the presence of n-butylamine, the D298A samples were
dialyzed into pH 6.8 buffer.  The UV/vis spectra of the samples biogenized in the
absence of n-butylamine remained at ~460 and ~480 nm (Figure 4.5 a) while the
spectra of the samples biogenized in the presence of n-butylamine shifted to ~480 and
~500 nm (Figure 4.5 b).  If the n-butylamine samples contained a TPQ cofactor, the
removal of n-butylamine should result in a shift in the spectra to ~460-480 nm as seen
in the D298A samples biogenized in the absence of n-butylamine.  However, this was
not the case, indicating that the species with an absorbance of ~480-500 nm is a
distinctly different species from TPQ and resembles that of LTQ in LOX and in
model compounds at the higher pHs.4,91
Figure 4.5 Final spectra of D298A biogenesis before — (pH 8.5) and after





































Enzyme samples biogenized in the presence of n-butylamine could be
producing a mixture of TPQ and LTQ cofactors, particularly at a lower pH.  The
combination of LTQ and TPQ cofactors in the pH 8.5 samples may contribute to the
difference in absorbance vs. pH 9 and 10 samples. As discussed in chapter 2, WT-
AGAO reacts with hydrazines to produce hydrazone-azo derivatives in tautomeric
equilibrium, but it exists primarily in the azo form.12,29,56 D298A has also been known
to react with hydrazines; however, the reaction occurred almost 200 x slower.46
Additionally, LTQ containing proteins have also been shown to react with hydrazines
to form, predominantly, the azo product.3 The reactions between WT- and D298A-
AGAO biogenized in the presence and absence of n-butyl amine with various
hydrazines, including 2-hydrazinopyridine, 2-phenylethylhydrazine, and
methylhydrazine, were monitored by UV/vis. WT-AGAO biogenized in the absence
of n-butylamine was the only species that resulted in an absorbance corresponding to
the hydrazone-azo derivative. Furthermore, prolonged incubation did not produce
hydrazone-azo derivatives, even with D298A biogenized in the absence of n-
butylamine that, in the literature, is reported to react slowly.46 Although the samples
did not react with the inhibitor, all of the samples were catalytically active with 2-
Sample Rate (mAbs/min(µM))
WT 17,110
WT with n-butylamine 417
D298A 96.4
D298A with n-butylamine 13.8
Table 4.3 Rates of catalysis with 2-phenylethylamine as a substrate.
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phenylethylamine as a substrate. Table 4.3 shows the rates of catalysis for each of the
samples.
The D298A sample, previously biogenized in the presence of n-butylamine
and after dialysis to removal excess amine, was incubated at 4°C, pH 8.5 for 1 month;
this resulted in a spectrum with one peak centered ~470 nm and another with a large
absorbance ~330 nm (Figure 4.6).  As seen in chapter 2, the final absorbance
spectrum of D298K had peaks centered ~450 nm and ~320 nm.  The final spectrum in
D298K was assigned to the LTI tautomer of LTQ.  It is possible that in D298A
biogenized in the presence of n-butylamine, the initial putative LTQ species is very
slowly converting to the more stable LTI tautomer as seen in D298K.
Attempts to determine the structure of the cofactors of WT and D298A
derived from the reaction with n-butylamine have recently begun using mass


















Figure 4.6 UV/vis spectrum of D298A biogenized in the presence of n-
butylamine at pH 8.5 after one month of incubation at 4°C.
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single needle shaped micro crystals that can be used as seed crystals in future crystal
optimization experiments (Figure 4.7).  The orange to red color of the crystals is
consistent with the color of the protein in solution at pH 6.8, both initially and after
one month.  Holo-WT crystals formed under similar conditions also have a red color
typical of the color of the protein in solution.5 A continuation of these studies is
required to determine the structure of the cofactor and its arrangement in the active
site of the protein.
Conclusion
In WT- and D298A-AGAO, the formation of TPQ occurs directly from the
Cu2+-bound tyrosine precursor where no spectroscopic intermediates have been
observed.  In D298K-AGAO, the direct conversion of the Tyr to LTQ was observed
by UV-vis spectroscopy. In the D298K mutant, the LTQ cofactor is formed through
Figure 4.7 Photograph of microcrystals of D298A biogenized in the presence of
n-butylamine
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the cross-linking of two amino acid residues, making it unable to rotate freely like the
TPQ cofactor.  In an attempt to generate an LTQ-like cofactor in AGAO that has an
increased mobility, WT- and D298A-AGAO were biogenized in the presence of n-
butylamine.
At pH 8.5 the biogenesis of WT and D298A cofactors in the absence of n-
butylamine resulted in species having &max of 475 and 460 nm, respectively, in
agreement with reports in the literature.35,46 However, the biogenesis in the presence
of n-butylamine hydrochloride resulted in peaks of 538 and 523 nm, respectively. It is
likely that an LTQ-like cofactor is being formed in both WT and D298A proteins
through the cross-linking of the free amine to the DPQ intermediate. This is further
supported by the observation that peaks at 330 and 470 nm are seen after a one month
incubation at 4°C, which correspond to the 320 and 450 nm peaks seen for the LTI
cofactor in D298K (chapter 2). The rate of biogenesis of D298A in the presence of
amine is faster than the rate in the absence of amine, but the opposite is true of WT.
This indicates that the active site of D298A is arranged in a way to better facilitate the
reaction between the amine and DPQ compared to WT.
In addition to the biogenesis of D298A at pH 8.5, the reactions were also run
at pH 9.0 and 10.0 which resulted in peaks that were ~20 nm red-shifted from those at
pH 8.5. It is possible that the hydrogen bonding interaction between O4 of the
quinone and Tyr284 is weaker at the higher pHs and allows for a greater extent of
electron density delocalization, leading to the red-shift observed in the absorbance
spectra. Dialysis into pH 6.8 buffer resulted in a ~20 nm blue-shift of D298A samples
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biogenized in the presence of n-butylamine, but not a ~50 nm shift, indicating that the
species is not TPQ but a different species that spectroscopically resembles LTQ. The
WT and D298A samples biogenized in the presence of amine and D298A biogenized
in the absence of amine, did not react with the inhibitor; however, all of the samples
exhibited catalytic activity that was 40- to 1000-fold less active than the wild-type.
Crystallographic studies may provide structural reasons for the variations seen in the
rates of catalysis.
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Chapter 5: Mutagenesis Study on the LTQ Precursor Lysine Residue in LOX
Introduction
Lysyl oxidase (LOX) belongs to a family of copper-containing amine
oxidases.  It has been known to play a role in stabilizing the extracellular matrix by
initiating the formation of intra-and intermolecular cross-links in collagen and
elastin.22,23 In humans, there are four lox-like (loxl) genes; each contains a ~ 630 bp
sequence at the 3’ end encoding the LOX catalytic domain.23 Three of the hloxl genes
(hloxl2, hloxl3, and hloxl4) contain four scavenger receptor cysteine rich (SRCR)
domains.108-113 SRCR proteins make up a family of cell-surface associated proteins
that function mainly within the immune system.114,115 SRCR domains are thought to
be involved in protein-protein interactions, mediate cell adhesion and/or cell
signaling.116 The specific role of the SRCR domains on HLOXL2-4 has not been
defined.  Abnormal expression of LOX has been associated with several disorders
including loose skin and joints and fibrotic diseases.22,117,118 High levels of HLOXL2
(at the mRNA level) have been seen in the reproductive tissues.108 Abnormally high
expression levels of HLOX and HLOXL2 (at the mRNA level) have been observed in
invasive breast cancer.  The expression of LOXL2 has been highly up-regulated in
metastatic but not nonmetastatic estrogen-dependent breast cancer cells (MCF7).119
When LOXL2 was expressed in MCF7, the cells changed their phenotype to become
invasive/metastatic and were surrounded by a high concentration of dense collagen
fibers.  However, MCF7 cells that do not express LOXL2 are not invasive, suggesting
that LOXL2 enhances the malignancy and the fibrosis of tumors. The mechanism of
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the up-regulation of LOXL2 expression seen in invasive and metastatic cell lines is
currently unclear.119-121 LOXL2 and LOXL3 have been proposed to oxidize two
specific lysine residues (K98 and K137) on the transcription factor Snail, that controls
epithelial-mesenchymal transitions (EMT).122 Overexpression of LOXL2 and LOXL3
induces EMT to downregulate E-cadherin expression implicated in the mechanism of
invasive and metastatic tumor progression.  E-cadherin is an epithelial protein that
mediates cell-cell interactions.123 Down regulation of the E-cadherin gene decreases
the strength of cellular adhesion and increases cell migration/invasion.122 Recently, a
study of LOXL2 expression by Hollosi and co-workers, has shown that LOXL2
expressed in malignantly transformed mammary cells demonstrated an altered
localization and processing when compared to LOXL2 expressed in normal
mammary epithelial cell lines.121 Elucidating the mechanism by which HLOXL2
reacts with the Snail transcription factor may provide insight into its role in metastatic
breast cancer.
Many studies have been performed to understand the mechanism of the
biogenesis of TPQ.5,9,14,29,30,55,64-74 It is widely accepted that TPQ is formed through a
self-catalyzed mechanism requiring Cu2+ and O2 with no help from other enzymes.
29,30
However, unlike the biogenesis mechanism of TPQ in CAO, little is known about the
biogenesis of LTQ in LOX. It has been suggested that a 1,4-addition of an !-amino
side chain of a lysine to a DPQ intermediate could form the LTQ cofactor.3 This
suggestion has been supported by a model study on the biogenesis of LTQ.1 The
study showed that the addition of n-butylamine to 4-ethylphenol in the presence of
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tyrosinase (to catalyze hydroxylation of the phenol and oxidation of the catechol)
produces a mixture of products.  This mixture was most likely formed due to the
amine reacting with the o-quinone in 1,2-, 1,4-, and 1,6- additions.  However, when
N-methyl-n-butylamine is used instead, only the product of the 1,4-addition is
observed, indicating a strong preference for 1,4-addition over 1,2- or 1,6-additions.
In order for the 1,4-addition to happen selectively in the enzyme, it was proposed that
the active site of LOX must be pre-organized.1 Bollinger and co-workers reported that
LTQ formation is also a self-catalyzed process using a recombinant LOXL1 from
Drosophila melanogaster.2 The study showed that denaturation with 6 M urea
followed by the extensive dialysis of the apo-form of a recombinant protein secreted
into the media of Drosophila S2 cells, with copper in air, leads to the formation of the
LTQ cofactor.  It was not clear why Cu2+ was not incorporated into the recombinant
protein that was secreted into the media containing 0.5 mM Cu2+.  The recombinant
HLOXL2 expression system produced in our lab (see materials and methods) yields
active holo protein that does not require manipulation.  Scheme 5.1 shows the
proposed biogenesis mechanism of LTQ.  Like the proposed biogenesis mechanism
for the formation of TPQ, DPQ has been proposed as an intermediate in the formation
of LTQ. In CAO, DPQ can be trapped with a lysine residue to form an LTQ like
species in D298K suggesting DPQ as a common intermediate in both the biogenesis
of TPQ in CAO and of LTQ in LOX.  In CAO, the C2 oxygen of TPQ was derived
from a solvent water molecule most likely involving the 1,4-addition of water to the
C2 position of the DPQ intermediate.66
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In order to identify the residues participating in the crosslink to form LTQ, a
mutagenesis study was done on LOX from a rat aorta expressed in Chinese hamster
ovary (CHO) cells.3 Lys314 and Tyr349 were identified as the precursors for the LTQ
cofactor from the sequence alignment with bovine aorta LOX where the structure of
LTQ was assigned. Activity assays showed that both of the single mutants of these
residues (K314A and Y349F), as well as the double mutant, were inactive. The study
did not, however, fully characterize the mutants. An immunoblot assay, probing with
rabbit antibodies of LOX, indicated that mutant protein concentrations ranged from
50 to 100% of wild type LOX. It is possible that the K314A mutant produced a TPQ-
like quinone that was inactive.  Additionally, Tyr349 may have undergone the initial
steps of biogenesis but was trapped in the form of one of the intermediates, thus being
unable to proceed in the biogenesis pathway. In order to examine these possibilities
and to understand the mechanism of LTQ cofactor biogenesis, the corresponding








































precursor lysine residue of the LTQ cofactor in the recombinant form of HLOXL2
expressed in S2 cells was mutated to an alanine. In addition to assessing the extent of
biogenesis, the effect of the mutation on the enzyme activity was also examined.
In order to determine which Lys residue in HLOXL2 corresponds to Lys314
in rat aorta LOX, a sequence alignment was performed.  Lys653 was identified as the





The site directed mutagenesis kit was purchased from Stratagene.  The
pMT/BiP/V5/His A vector was purchased from Invitrogen. The pASK-IBA3 vector
Figure 5.1 Sequence alignment between HLOXL2 and RLOX.  K314 of LOX from
a rat aorta corresponds to K653 in human LOXL2 protein. The alignment was done
through the MultAlin website (http://bioinfo.genotoul.fr/multalin/multalin.html)
and the results were exported to the ESPript 2.2 website
(http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) for graphic representation. The
blue star indicates the lysine precursor. The orange star indicates the tyrosine
precursor. The green stars indicate the proposed copper-binding site.
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and the strep MBA-classic HRP conjugated antibody were purchased from IBA.
PVDF membranes, PMSF, pepstatin A, leupeptin, Tris, sodium chloride, SDS, urea,
sodium and potassium phosphates, and #-mercaptoethanol were purchased from
Fisher Scientific. Antipain, serum free media and copper sulfate were purchased from
Sigma Aldrich. Glycerol (85%) was purchased from Acros. Penicillin-streptomycin,
Schneider’s Drosophila Medium, fetal bovine serum, the biotinylated protein marker,
the anti-biotin HRP linked antibody, LumiGlo reagents A and B for
chemilluminescent detection and blasticidin were purchased from Invitrogen.  Tween-
20, and prestained low molecular weight protein marker were purchased from
BioRad.  Bovine serum albumin (BSA) was purchased from MP Biomedicals LLC.
Proteinase K was purchased from Ambion.  BioMix PCR enzyme was purchased
from BioLine.  Nonidet P-40 was purchased from AppliChem.  The SuperFect
reagent was purchased from Qiagen.  All plasticware was purchased from MidSci.
Synthetic oligonucleotides were purchased from Operon Biotechnologies, Inc.  PCR
was performed on a DNA Engine PTC-200 Peltier Thermal Cycler (BioRad).
Plasmids were prepared using a QIAprep Spin Miniprep kit (Qiagen).  DNA
sequencing was performed at the UC Berkeley DNA sequencing facility. Western
Blots were exposed to Classic Blue Autoradiography Film BX from MidSci and
developed using an SRX-101A Konica Minolta processor.
Cloning
A cDNA containing the ORF of hloxl2 was purchased from Origene. A 1.023
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Kb cDNA coding one SRCR domain, and the LOX core domain of HLOXL2 ("1-3
srcr hloxl2) was amplified and cloned into pASK-IBA3 (IBA, Germany) between the
BsaI restriction sites in order to incorporate the Strep tagII-coding sequence at the 3(
end. The "1-3 srcr-hloxl2 + strep was excised by PCR using a set of primers to
engineer a SpeI (5( end) and XhoI (3( end) restriction enzyme sites and the SpeI/XhoI
digested product was inserted into the pMT/Bip/V5-HisA vector between SpeI and
XhoI restriction sites. The sequence was verified by DNA sequencing at UC Berkeley
DNA sequencing facility. The resulting plasmid is termed, pMT/BiP/"1-3 srcr
hloxl2/strep and contains a BiP excretion signal, the gene of interest, and a strep tag
in a pMT vector.124
Site-directed Mutagenesis
The expression plasmid for K653A of "1-3 SRCR HLOXL2 was generated
by site-directed mutagenesis using a QuikChange mutagenesis kit from Stratagene
using pMT/BiP/"1-3 srcr hloxl2/strep as the parent vector.  The DNA primers used
for K653A mutagenesis were 5(-GGCAGAGGGCCACGCGGCCAGCTTCTGC-3(
(forward) and 5(-GCAGAAGCTGGCCGCGTGGCCCTCTGCC-3 ( (reverse)
(underlined nucleotides correspond to the sites of mutation). The gene of interest in
the plasmid was sequenced in both directions and the point mutation was confirmed.
Transfection and Selection
The plasmid was co-transfected with the blasticidin selection vector, pCoBlast
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(Invitrogen), into 3 mL of 2x106 Drosophila S2 cells using the SuperFect transfection
reagent (Qiagen) according to the SuperFect Transfection Reagent Handbook. For the
selection, the transfected cells were maintained in a 5 mL of Drosophila complete
medium containing Blastcidin for four weeks, according to the Drosophila
Expression System manual, version F (Invitrogen). Dead cells were observed after
~10 days.  S2 cells were grown at 27°C.
After three to four weeks of selection, cell lines were expanded to 5 mL T-
flasks at 2 x 106 cells/mL.  Cells were transferred at a concentration of 1 x 104
cells/mL, to an eppendorf tube and centrifuged at 1,000 rpm for 5 min.  The
supernatant was removed and the cells were resuspended in 200 µL of cell lysis
solution containing 0.5% Tween-20, and 60 µg/mL proteinase K in water.125 The
mixture was incubated at 56°C for 4 hrs followed by 95°C for 30 min.  The mixture
was stored at 4°C.  PCR was performed on the lysate using the BioMix PCR enzyme.
The PCR primers used were 5’-TGTGTAAAGCCGCGTTTC-3’ (forward) and 5’-
CCGCTCGAGTTATTTTTCGAACTGCGGGT-3’ (reverse).  A DNA gel (1%
agarose) was run to evaluate the integration of the gene of interest in the genomic
DNA of the S2 cells. Aliquots of the PCR-verified clones (stable cells) were stored in
liquid N2.
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Cell Expansion and Passaging
Stable cells were expanded/passaged when cells reached a density of 8 x 106
to 1 x 107 cells/mL.  Cells were seeded at 2 x 106 cells/mL according to the
Drosophila Expression System manual, version F (Invitrogen).
Protein Expression and Western Blotting
Protein was expressed by the addition of CuSO4 (final concentration 0.6 mM)
to a 15 mL T-flask containing cells at 4 x 106 cells/mL in serum free media. Cells and
media (5 mL) were harvested 3-5 days post induction and centrifuged at 1,000 rpm
for 8 min. Protease inhibitors (1 µL of 1,000x), PMSF, pepstatin A, leupeptin, and
antipain, were added to 1 mL of media.  Media and cells were frozen at -20°C until
further use.  Samples were thawed and 500 µL PBS buffer was used to resuspend
cells.  The mixture was centrifuged at 12,000 x g for 5 min and the supernatant was
discarded. Protease inhibitors (0.1 µL of 1,000x) were added to the cells, and the cells
were resuspended in 50 µL lysis buffer containing 50 mM Tris buffer, 150 mM NaCl,
and 1% Nonidet P-40 at pH 7.8.  The cells were incubated in lysis buffer for 10 min
at 37°C.  The lysis product was centrifuged at 12,000 x g for 5 min.   The supernatant
was set aside for Western blotting.  The insoluble fraction was incubated overnight at
4°C in a 100 µL SDS solution containing 250 µL Tris pH 6.8, 30 % glycerol, 8 % #-
mercaptoethanol, and 80 mg/mL SDS.  The sample was centrifuged at 12,000 x g for
5 min and the supernatant was set aside for Western blotting. Urea (100 µL of 6 M)
was added to the insoluble portion, and the sample was boiled for 5 min.  SDS-PAGE
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was run on samples of media (neat) separately from samples of lysis supernatant (5
µL in a total of 20 µL containing 1x sample buffer), SDS supernatant (neat), and the
insoluble portion of the cells in 6 M urea (neat).  A control of the wild-type "1-3
SRCR HLOXL2 (neat from media), biotinylated marker, and a pre-stained low
molecular weight marker were run on each gel.  Once the transfer to a PVDF
membrane was complete, the membrane was washed 3 times with PBS buffer for 5
min each. The membrane was blocked for 1 hr with a 3% BSA solution containing 15
mL PBS, 0.75 mL Tween-20, and 0.45 g BSA.  The membrane was then washed 3
times with PBST for 5 min each followed by incubation with 1° antibody (10 mL
PBST, 2 µL anti-biotin antibody (Invitrogen) for detection of the biotin marker, and 3
µL pre-diluted strep MBA-classic HRP conjugated antibody (IBA) for protein
detection) overnight. The membrane was washed two times with PBST and two times
with PBS for 5 min each.  This procedure was completed according to the strep
MBA-classic HRP conjugated antibody directions from IBA.  The membrane was
incubated for 2 min in a chemilluminescent reagent (Invitrogen) before exposure to
autoradiography film and development.
Results
Transfection and Selection of Stable Cell Lines
Co-transfection of plasmid containing the K653A mutant of "1-3 srcr hloxl2
and plasmid containing pCoBlast selection marker was done in 12 wells from two 6
well plates making 12 independent cell lines.  Half were transfected, followed in two
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weeks by the other half.  The addition of blasticidin to the media started the selection
process.  Cells that have both the blastcidin resistance and the gene of interest
integrated into the genomic DNA survived during blastcidin selection.  Dead cells
were seen at ~10 days.  Stable cell line selection occurred over a 4 week period.
However, blasticidin continued to be added to all passaged or expanded populations
in a volume of 5 mL or less.
Once stable cell lines were selected, PCR was performed to evaluate the
integration of K653A mutant of "1-3 srcr hloxl2 into the genomic DNA of the S2
cells.  DNA gels of the PCR products reveal that the gene of 1.1 kb was incorporated
into the genomic DNA in each of the 12 cell lines (Figure 5.2 shows the DNA gel for
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Figure 5.2 DNA gel of "1-3 srcr hloxl2 K653A PCR product. Lane 1: marker;
lane 2: PCR product
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Protein Expression and Western Blotting
Protein production was induced by the addition of CuSO4 (final concentration
of 0.6 mM) to 15 mL of 4x106 cells/mL.  Cells and media were harvested after 3 days
and separated by centrifugation. A western blot of the media showed no mutant
protein present in the media (Figure 5.3 a).   A monoclonal antibody specific for the
Strep tagII was used for protein detection.  A BiP signal at the 5’ end of the gene
should have directed the secretion of the expressed protein from the cell if it was
folded like the wild-type.  The absence of secreted protein in the media indicated that
the protein was either not expressed, or it was being expressed but not secreted.  To
investigate this further, another 15 mL of cells were induced.  The cells were
harvested after 3 days and separated from the media.  The cells were lysed in the
presence of 1% Nonidet to help solubilize proteins.  The soluble lysate was removed
Figure 5.3 Western blot of "1-3 SRCR HLOXL2 expressed in S2 cells a) media
fractions, lane 1: prestained SDS-PAGE marker; lane 2: K653A mutant; lane 3:
WT,  b) cytosolic fractions, lane 1: biotin marker; lane 2: low molecular weight
marker; lane 3: soluble fraction; lane 4: 30% SDS extractable fraction; lane 5:
insoluble fraction extracted with 6 M urea; lane 6: WT HLOXL2 control in media

















after centrifugation and the insoluble portion of the cells were further incubated in a
solution of SDS.  Again the soluble portion of the SDS treated sample was removed
after centrifugation and 6 M urea was added to the pellet.  A Western blot was run on
each of these fractions (Figure 5.3 b), and the HRP conjugated anti-strep antibody
was used for protein detection. The results of the western blot indicate that the mutant
protein was expressed in the cytosol but not secreted. Each of the fractions had a band
that was similar in size to the wild-type "1-3 SRCR HLOXL2 that was secreted into
the media. The protein in the cell appears to be mostly insoluble, likely in the form of
an inclusion body. Most likely the protein was misfolded, the BiP signal was not
exposed, and thus the protein was not secreted.  A small amount of protein is soluble
in Nonident-containing lysis buffer.  Further investigation is required to determine if
any solubilized protein can be purified from the cell and analyzed.
Wild-type "1-3 SRCR HLOXL2 expressed in the media should have the BiP
signal cleaved off making the predicted molecular weight ~41 kDa; however, on the
western blot, the molecular weight is observed ~48 kDa.  Similarly, the K653A
mutant of "1-3 SRCR HLOXL2 expressed in the cytosol likely retains the BiP signal
making the predicted molecular weight ~42.6 kDa while the observed molecular
weight is ~48 kDa.  An SDS-PAGE gel of the purified wild-type "1-3 SRCR
HLOXL2 indicates a molecular weight just above 45 kDa. The discrepancy in the
apparent and predicted molecular weights of the proteins is unclear.  The retention of
the BiP signal would only account for a ~2 kDa increase in molecular weight, not the
~7 kDa increase that is observed. It is possible that the protein is glycosylated. Two
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potential N-glycosylation sites have been identified in "1-3 SRCR HLOXL2;111
however, the presence of glycosylation at these sites has not been identified.  In order
to check for glycosylation, the protein should be incubated with deglycosylase prior
to SDS-PAGE.  Additionally, the purified protein could be analyzed by mass
spectroscopy to determine the exact mass of the protein.
The cytosolic expression of the K653 mutant of "1-3 SRCR HLOXL2 might
explain the results found by Wang and co-workers.3 A full-length lox from rat aorta
was expressed in CHO cells and the processed LOX was secreted in the culture
media.  In comparison with the wild-type, the corresponding mutant, K314A, only
showed negligible activity in the media.  While the study reported that the WT
protein was secreted to the media, it is unclear about the subcellular localization of
mutant proteins. It is possible that the lack of activity observed in the media was due
to the absence of protein, as seen in the current study.
Conclusion
Scheme 5.1 shows the proposed biogenesis mechanism of LTQ.  In the
proposed mechanisms of biogenesis for TPQ and LTQ, DPQ has been proposed as an
intermediate. In CAO, DPQ can be trapped with a lysine residue to form an LTQ like
species in D298K, suggesting DPQ as a common intermediate in both TPQ and LTQ
biogenesis.
A mutagenesis study of LOX from a rat aorta expressed in CHO cells
supported that Lys314 and Tyr349 are the precursors for the LTQ cofactor.3
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Mutagenesis of these residues was performed followed by activity assays that showed
both of the single mutants of these residues, as well as the double mutant, were
inactive. The study did not, however, fully characterize the mutants. In an attempt to
characterize the corresponding mutants of the recombinant HLOXL2, and to gain a
better understanding of the mechanism of LTQ cofactor biogenesis, the
corresponding Lys in HLOXL2 was mutated to an Ala (K653A).
In the present study, Drosophila S2 stable cells for the expression of the
K653A mutant of "1-3 SRCR HLOXL2 were selected.  The protein was expressed
but was not secreted into the media despite the presence of a BiP secretion signal.
The western blot results showed that the protein was expressed in the cytosol of the
cell mostly as insoluble fractions, indicating that the protein was likely mis-folded
into an inclusion body and the BiP signal was inaccessible, preventing protein
secretion.  The Lys653 residue is clearly involved in the proper folding of the protein
in addition to being involved in the crosslink to form LTQ.  Further studies will be
needed to test for the proper folding of any solubilized protein from the cytosol and, if
folded properly, to characterize the structure of the cofactor, to determine the
enzymatic activity, and to gain a better understanding of the mechanism of LTQ
c o f a c t o r  b i o g e n e s i s .
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Chapter 6: Final Conclusions
Mutation of an active site residue in AGAO to a lysine, D298K, can
effectively trap the DPQ intermediate and confirms the intermediacy of DPQ in TPQ
biogenesis. This finding further supports the proposed intermediacy of DPQ in the
biogenesis of LTQ. Additionally, the incorporation of the lysine residue in the
Asp298 position of AGAO to trap DPQ, shows that the DPQ intermediate has
mobility and can leave the active site copper and enter the wedge shaped cavity to
react with Lys298.
Two distinct species are formed during cofactor biogenesis in D298K. The
first, proposed to be an LTQ-like quinone, forms at ~ 500 nm at a similar rate as the
formation of TPQ in WT AGAO. Therefore, it is likely that the initial steps of
biogenesis, Tyr382 activation and oxidation to DPQ, are not affected by the mutation
of D298K. The second species forms ~ 450 nm and has been proposed to be LTI, the
tautomer of LTQ. The crystal structure of D298K suggests a hydrogen bonding
interaction between the O4 of the quinone and Tyr284. This hydrogen bond has been
shown to stabilize the quinone in the form of the LTI tautomer and disruption of the
hydrogen bond by mutation results in an unstable protein with a &max of ~505 nm, like
that of LTQ. The natural cofactor in LOX is LTQ with an absorbance of ~ 505 nm,
suggesting that the corresponding carbonyl group of LTQ does not have such a
hydrogen bonding interaction in the active site of LOX.
TPQ was not detected at any point during the biogenesis of D298K in the pH
range studied (6.8 to 9.5). This indicates that amination can effectively out compete
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hydration by a copper-associated water molecule, even though hydration occurs in the
natural reaction. Changing the pH did have an affect on the &max of the LTQ-like
species. As the pH increased from 6.8 to 9.5, the &max shifted from ~ 496 nm to ~ 518
nm, most likely corresponding to the amount of LTI present at the end of the first
phase.
The pH profile of D298K biogenesis showed a pH-dependence on rate for
both the 505 and 450 nm species. The pH-dependency for the rate of the LTQ-like
species showed a bell-shaped curve with pKas of 7.93 ± 0.10 and 9.62 ± 0.13,
respectively with a maximum rate at ~ pH 8.8. The residue responsible for the pKa of
7.93 ± 0.10 is deprotonated when the rate is the fastest and was assigned to the
precursor tyrosine (Y382). The residue responsible for the pKa of 9.62 ± 0.13 is
protonated when the rate is the fastest and was assigned to Tyr284. It is likely that
Tyr284 is responsible for holding DPQ in the wedge shaped cavity, through a
hydrogen bond, to react with Lys298.
The pH-dependency for the rate of conversion of the LTQ-like species to LTI
occurred with a pKa of 7.68 ± 0.086 that was also assigned to Tyr284. Tyr284 is
known to hydrogen bond to LTQ/LTI to stabilize the LTI tautomer. Therefore,
deprotonation of this residue may be influencing the thermodynamic equilibrium.
In the initial minute of cofactor biogenesis of both WT- and D298K-AGAO, a
~ 370 nm absorbance was observed. This species is proposed to be a charge transfer
species where the formation is not O2-dependent. The species is likely formed off the
reaction pathway, as this species was not observed to convert to cofactor in an
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isosbestic manner. However, it is likely that the formation of this species involves
Cu2+ in the active site of the protein, due to the observation that it was not formed in
the Zn2+-substituted enzyme.
The LTQ-like species formed in D298K is trapped in the flipped, inactive
conformation because the cross-link is formed between two amino acid residues. In
an attempt to generate an LTQ-like cofactor in AGAO that has an increased mobility
and is potentially in the active conformation, WT- and D298A-AGAO were
biogenized in the presence of n-butylamine hydrochloride. Typical peaks for the
biogenesis in the absence of amine to form the TPQ cofactor in WT and D298A are
475 and 460 nm, respectively. However, when biogenesis occurred in the presence of
n-butylamine, peaks at 538 and 523 nm were observed for WT and D298A,
respectively; TPQ was not detected. This most likely indicates the formation of an
LTQ-like cofactor. After incubation at 4°C for one month, peaks were observed at
330 and 470 nm, which correspond to the peaks at 320 and 450 nm observed for LTI
in D298K. Other than the WT-sample biogenized in the absence of amine, the
samples did not react with inhibitors but all of the samples showed catalytic activity
that was 40- to 1000- fold less than WT.
As with the biogenesis of TPQ in CAO, DPQ has also been proposed as a
biogenic intermediate in the formation of LTQ in LOX. The formation of an LTQ-
like cofactor in AGAO supports this proposal but is not conclusive. An attempt to
generate a TPQ cofactor in LOX was made to evaluate this proposal. In addition to
the possibility of forming TPQ, it is possible that the reaction would be incomplete
128
and DPQ would be observed directly. The mutation of Lys653 to Ala in a
recombinant form of HLOXL2, resulted in the formation of a mis-folded protein that
was expressed mainly as an inclusion body in Drosophila S2 cells.  Although the
conclusive identification of DPQ as an intermediate on the pathway to form LTQ was
not confirmed, this result shows that Lys653 is important to the proper folding of the
protein as well as the formation of LTQ.
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